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ABSTRACT 
Age and hypertension lead to aortic remodeling and stiffness and are also 
major risk factors for abdominal aortic aneurysms (AAA). This study aimed to 
investigate: (i) the use of multimodal imaging to test the hypothesis that 
aneurysmal disease of the abdominal aorta is a remodeling response to aortic 
stiffness and systolic hypertension; (ii) the utility of a novel ultrasound-based 
device (AortaScan) for detection of AAA in the community setting. 
We used multimodality imaging tonometry and cardiovascular magnetic 
resonance imaging (CMR) to quantify pulse wave velocity (PWV, a measure of 
stiffness), in the aortic arch (Arch), thoracic aorta (TA) and the abdominal aorta 
(AA). Stiffness was also correlated with measures of calcification and metabolic 
activity measured on CT and PET/CT respectively. 
The thoracic aortae of patients with AAA were stiffer than those of sex matched 
controls. Although systolic hypertension was more common in AAA patients, 
multivariate analysis revealed that aortic stiffness and mean arterial pressure 
were associated with AAA disease. The likelihood of developing AAA disease 
increases >3-fold for 1m/sec increase in PWV.  This data suggests that 
segmental stiffness is modified in the presence of AAA and provides further 
evidence that aneurysm formation may be an adaptive remodeling response to 
hypertension.  
The AortaScan can detect AAA without the need for a trained operator and has 
potential in a community-based screening programme. It would, however, need 
further technical improvement to increase sensitivity before it could be 
considered a replacement for trained screening personnel. 
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CHAPTER 1   
General introduction 
 
1.1 Abdominal aortic aneurysm 
Abdominal aortic aneurysm (AAA) is found in 6% of men and rupture is 
associated with a high morbidity and 80-90% mortality. Age and male sex are 
the two well-known risk factors for AAA development. Currently the aortic 
diameter is the only feature that is used to predict the risk of rupture. The other 
recognised risk factors for continued expansion of the aneurysm include 
smoking, female gender and higher mean blood pressure. More recently 
developments in imaging have allowed other features of the AAA to be 
proposed as predictors of rupture risk; these include arterial wall stiffness, 
intraluminal thrombus (ILT), wall tension and peak wall stress1.  
1.1.1 Definition small/large AAA 
‘Aneurysm’ is derived from the Greek word ‘aneurusma’, meaning widening, 
and can be defined as a localised dilatation of a vessel2. An artery is considered 
aneurysmal if the size is >50 % of its original diameter. In the abdominal aorta, 
it is defined as an aneurysm if the diameter is >3cm3. An infra-renal AAA is 
called small if the size is < 5.5cm and large if size is > 5.5cm. 
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 Fig 1-1: 3-dimensional reconstruction of CTA showing an abdominal aortic 
aneurysm in 74 year old male (CTA-computed tomography angiogram) 
 
1.1.2 Pathogenesis of AAA 
Multiple factors are involved in the pathogenesis of AAA. The main 
characteristic of an abdominal aortic aneurysm (AAA) is the loss of the medial 
elastic fibers by connective tissue, with a net loss of elastic properties, increase 
in diameter and, finally, wall rupture. There is destruction of medial and 
adventitial collagen, medial smooth muscle cells, wall infiltration by lymphocytes 
and macrophages with neovascularization4,5. Other factors, such as blood flow, 
parietal calcification, intra-luminal thrombus and maximum diameter, may also 
affect the behaviour of the aortic wall6,7.  
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Fig 1-2: Hypothetical aortic remodeling hypothesis. Mechanism of aortic stiffness is 
complex, ageing and smoking cause stiffness leading to hypertension. Aorta remodels 
to combat hypertension. Remodeling in early stages causes stiffness and later 
dilatation as a beneficial effect. 
 
1.1.3 Aortic remodelling and stiffening 
Aorta is an elastic artery. AAA pathophysiology remains complex. 
Atherosclerosis has some contribution to AAA pathogenesis8, but is more 
prevalent in patients with atherothrombotic disease9. It has been suggested that 
the mechanism that regulates the development of AAA is independent of 
atherosclerosis and is a local manifestation of a systematic disease10. Age, 
hypertension (HTN) and diabetes mellitus lead to reduction in elastic content of 
the aorta11 and are associated with an increase in stiffness of elastic arteries12 . 
HTN causing AAA is less defined13-14 but it contributes to aneurysm rupture 15. 
Blood pressure in the abdominal aorta is higher than that of the thoracic aorta 
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as a result of reduced elastin content and a greater collagen content11,16, 
contributes to a greater stiffness in this segment.  
Aberrant arterial remodeling has a pivotal role in the development of AAA17. 
Dilatation (which like stiffening is a strongly age related phenomenon) may 
occur as a remodeling process in response to the intrinsic stiffening of the wall 
offsetting the effects of intrinsic stiffening on systolic/pulse pressure by 
increasing functional compliance (~ stiffness x diameter)18. An excessive 
propensity to dilatation, in combination with additional local stimuli (e.g. 
atherosclerotic plaque) may result in aneurysm formation.  AAA enlargement is 
related to remodeling of the extracellular matrix, particularly collagen and elastin 
metabolism19 , whilst there is general consensus that ruptures are a multi-
factorial process involving a complex interaction between mechanical forces 
and local cellular activity and remodeling2, 20.  
The mechanism of arterial stiffening is complex and mainly affects elastic 
arteries. Like AAA formation, stiffness is possibly caused by fracture of elastin 
and deposition of collagen within the media of an artery21. Calcification further 
complicates this process22. Muscular arteries are not affected by changes in 
blood pressure and age23, 24.  In a longitudinal study it has been shown that 
brachial artery stiffness reduces as an adaptive response to progressive 
increase in aortic stiffness25.  
Mechanisms of calcification    
This is relatively little detailed knowledge of the mechanisms that regulate 
arterial stiffening and calcification. The type of calcium crystal that accumulates 
in the blood vessel wall exists mostly in the form of calcium apatite, which is the 
type of mineral found in bone26.  
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Micro-particles released from vascular smooth muscle cells (VSMCs) in 
response to mechanical stimuli and inflammatory cytokines are thought to 
induce matrix degradation and initiate an osteogenic process leading to 
calcification27.  Oxidative stress, bone morphogenic proteins (BMPs) or changes 
in pyrophosphate levels promote VSMCs to undergo osteogenic 
differentiation28. Calcification is regulated as an active process by inhibitors 
(present in micro-particles) including fetuin-A, matrix Gla protein (MGP) and 
osteoprotegrin/ rank ligand (OPG/RANKL)26-27, 29-30. The level of circulating OPG 
is independently predictive of cardiovascular events in man31 and is also weakly 
associated with aneurysm progression32. Fetuin-A is synthesized in liver and 
secreted in blood. Its deficiency is associated with soft tissue calcification in 
mice and humans30. The precise molecular mechanism of MGP function is not 
known, although it was thought for some time to act by binding excess calcium 
ions or small crystals in tissues and clearing them to the circulation26. It is found 
to be a component of a serum complex consisting of hydroxyapatite, fetuin and 
other proteins33. 
Vascular calcification can occur in two sites in the arterial wall: the intima and 
the media. Intimal calcification is associated with atherosclerosis, while medial 
calcification exists independently of atherosclerosis and is associated with 
elastin and vascular smooth muscle cells34. 
1.2 Properties of the aortic wall 
Diameter, pulse wave velocity (PWV), arterial stiffness, elasticity, peak wall 
stress (PWS), compliance, distensibility and pressure-strain modulus (Ep) 
describe a range of properties of the aortic wall that have been described to 
predict aneurysm expansion or rupture (Table 1-1). Identification of an 
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individual’s aneurysm progression and rupture risk by non invasive imaging 
could allow selection of patients with small AAA for early repair.  
1.3 Aneurysm surveillance 
Randomized control trials, the UK Small Aneurysm Trial (UKSAT) and the 
Aneurysm Detection and Management (ADAM) study, have shown that patients 
with small AAA can safely be kept on surveillance programmes13,35. There is 
still, however, much debate as to whether surveillance is appropriate for all 
patients with small AAA as some may be at increased risk of rupture36. In the 
Multicentre Aneurysm Screening Study (MASS Trial) 5% of the patients 
undergoing ultrasound surveillance died from aneurysm related causes; either 
after rupture or symptom onset that led to urgent surgery37.  Autopsy studies 
show that 10-24% of all ruptured AAA have a diameter <5.5cm38-39. The UKSAT 
trial showed that more than 60% of patients with small aneurysms required 
surgery within six years35. This is predominantly for reaching size criteria but 
also for symptom onset. This has led some to argue that it may be safer to 
operate on some patients with small AAA. This is more the case now with the 
widespread application of endovascular stent repair, with potentially lower 
procedural risks. Two randomized control trials, Comparison of surveillance vs. 
Aortic Endografting for Small Aneurysm Repair40 (CAESAR) and Positive 
Impact of endoVascular Options for Treating Aneurysm early41 (PIVOTAL) have 
failed to show any survival benefit of an early endovascular aneurysm repair 
(EVAR) versus surveillance of subjects with small AAA. Although these trials 
failed to demonstrate an overall benefit as a group, there appears to be a 
clinical advantage in selecting patients at higher risk of early rupture at a small 
size to be treated. 
 
 22 
There are a number of techniques available to facilitate aneurysm surveillance: 
(sections 1.3.1 to 1.3.5 are part of my published work42) 
1.3.1 Ultrasound 
Currently, the best determinant of the risk of AAA rupture is the maximum 
diameter43. Ultrasound (US) has been used since the early 1960s to measure 
AAA diameter and it has a sensitivity approaching 100% to detect AAA44. 
Although ultrasound is operator dependent the measurements are reproducible. 
It is non-invasive, easily available, cost effective and modern portable scanners 
allow community based screening and surveillance. Recent advances include 
devices like AortaScan that automatically detect the aortic diameter with 90% 
sensitivity without the need for a trained operator45. Ultrasound tends to 
measure AAA diameter slightly smaller than CT scan46.    
The UKSAT showed that patterns of expansion are highly variable. Certain 
patients having a uniform rate of aneurysm expansion, some aneurysms grow 
in intermittent bursts whereas certain aneurysms remaining stable. Traditionally 
expansion rates of greater than 1cm per year or 0.5cm per 6 months have been 
used as indicators of increased rupture risk but this is not borne out in data from 
the UKSAT study47. These criteria have therefore not been included as a 
reason to refer a patient with a small AAA for vascular specialist assessment in 
the National AAA Screening Programme (NAAASP).    
Ultrasound has also been used to measure the compliance and distensibility of 
AAA. Compliance is a measure that reflects mechanical properties of the aortic 
wall and increases with AAA diameter48 (Table 1-1). AAA expansion is the 
result of wall remodeling and this is reflected by changes in compliance.  Tissue 
Doppler imaging (TDI) measures compliance by utilizing the Doppler effect to 
assess wall displacement at points along the aorta during the cardiac cycle. 
 23 
Compliance is calculated from the amount of displacement of the vessel wall 
and the measured blood pressure. Long et al demonstrated a correlation 
between compliance and aortic size using TDI. There was significant positive 
linear relationship between maximum diameter and segmental compliance, but 
not with the pressure strain modulus or stiffness49.  Further studies are now 
required to assess whether compliance measured during routine AAA 
ultrasound monitoring using TDI could be a predictor of expansion.  
Distensibility is expressed as the relative change in vessel cross-sectional area 
that occurs during the cardiac cycle, divided by the corresponding change in 
blood pressure (Table 1). Pressure strain modulus (Ep)  is a measure of stiffness 
(β) or lack of elasticity of an artery20 . If Ep and β are higher then the artery is 
less distensible and has lower arterial wall compliance48. These characteristics 
differ from compliance in that they are measures of the amount of change in 
diameter with pressure change, whereas compliance reflects the rate of that 
change. Aortic distensibility decreases with age and can be measured non-
invasively by either an ultrasound scan-based echo tracking technique 
(Diamove)48, ECG-gated CT50 or MRI51. All of these use an estimated central 
blood pressure value from sphygmomanometer to calculate compliance; this 
may be inaccurate in certain cases. The Diamove48, 52 device uses a 3.5-MHz 
B-mode ultrasound probe to produce an image of the aorta or aneurysm. The 
anterior and posterior walls are then tracked and the change of vessel diameter 
during each cardiac cycle is measured. The acquired data is analyzed to 
calculate the distensibility. Diamove can also measure diameter and compliance 
with acceptable reproducibility53. A prospective multi-centre study showed that a 
reduction in distensibility over time (increase in Ep) significantly reduced the 
time to rupture independently of aneurysm diameter52. Baseline aortic wall 
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distensibility may provide an additional parameter for AAA to optimize the 
indication and time for elective repair54.  
 
Vibrometry is a novel use of ultrasound to estimate wall stress in rubber tube 
models of aneurysm sac and may have potential to predict the risk of rupture in 
AAA55.  Ultrasound can also be used to map the propagation of pulse wave 
along the aneurysm wall and this has been described as a tool that may predict 
AAA rupture56. Wall stress and PWV are discussed in detail on sections on CT 
and MRI respectively. 
The above evidence suggests that ultrasound can be used to measure multiple 
dynamic properties of the aortic wall in addition to its diameter. These 
parameters may make US a better tool to predict AAA expansion or rupture.             
1.3.2 Computed tomography (CT) 
CT scanning accurately diagnoses abdominal aortic aneurysms and is 
commonly used for assessment of anatomy prior to endovascular or open             
aneurysm repair. Supplementary data regarding proximal and distal aneurysm 
extension in relationship to branches, characteristics of intraluminal thrombus, 
and aortic neck length, diameter and angulation can all be obtained by CT. In 
addition to anatomical details CT also provides information on aortic wall 
calcification. As discussed above CT can be used to measure distensibility 50 . 
Distensibility is reduced within the aneurysmal segment compared to normal 
proximal aorta in both small and large AAA. It has been suggested that changes 
in distensibility might affect the risk of subsequent aneurysm formation57.  
Nearly 75% of all AAAs have varying degrees of intraluminal thrombus (ILT)58. 
The role of ILT in predicting expansion or rupture is much debated. In one study 
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it was found that aneurysm wall covered with thrombus is thinner and shows 
signs of inflammation and apoptosis of smooth muscle cells. These findings 
may be related to a reduced structural integrity and stability of the wall and an 
increased risk of rupture59. The presence of ILT in AAA may affect intra-
aneurysmal pressure which may in-turn cause rupture. Schurink et al. showed 
that ILT does not reduce the mean blood pressure or the pulse pressure near 
the aneurysmal wall and therefore does not reduce aneurysm rupture risk 60 but 
Stenbaek et al. support that thrombus and its growth rate are associated with 
an increased risk of AAA rupture61. There is however no overwhelming 
evidence related to the consequences of ILT. 
1.3.3 Functional imaging of AAA by positron emission topography (PET) 
PET offers the possibility of using radiotracers to image functional activity in the 
wall of the aorta62-67. Currently one of the tracers with clinical application is the 
glucose analogue 18-fluorine (18F) flurodeoxyglucose (FDG). It enables 
detection of increased glucose metabolism. Increased uptake is characteristic of 
many cancers and other non-malignant processes such as infection and 
inflammation68. It could therefore potentially assess the metabolic activity in the 
aneurysmal wall69. FDG uptake is expressed as standardized uptake values 
(SUV), for tissue attenuation. The SUV is calculated either pixel-wise or over a 
region of interest for each image.  
Increase enzyme and cellular activity in the AAA wall are seen histologically at 
the site of rupture and these ‘hot spots’ may be responsible for focal weakening 
and rupture at relatively low levels of intraluminal pressure 70-71. FDG-PET/CT is 
a promising technique that may identify such areas of activity and thus be able 
to predict an increased risk of growth or rupture65,69-71. PET-CT imaging with 18-
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fluorine (18F)-labeled nanoparticles allows quantification of macrophage content 
in a mouse model of AAA72. 
Maximum aortic FDG uptake correlates with both the histopathologic 
characteristics of unstable aneurysm wall and clinical symptoms64.  The 
intensity of the FDG signal significantly correlates with tissue inflammation, 
increased macrophage and T-cell accumulation and matrix metalloproteinase-9 
(MMP-9), the activity of which associated with aneurysm rupture73. Patients with 
AAA have a significantly increased FDG uptake compared with normal aortas66. 
Similarly significantly higher uptake is observed in inflammatory aneurysms 
compared with non-inflammatory aneurysms63.  Furthermore, FDG uptake in 
aortic wall seems to increase with age and is not related to calcification68. The 
preliminary findings from an observational longitudinal pilot study suggest that 
there is an inverse trend between FDG uptake on PET and future AAA 
expansion, suggesting that aortic aneurysms with lower metabolic activity are 
more likely to expand72. 
As discussed above, aneurysm enlargement has been associated with growth 
of intraluminal thrombus61. This thrombus is biologically active with constant 
turnover due to platelet activation and phosphatidylserine exposure at the 
interface with circulating blood74. 99mTc-annexin-V (ANX) is a tracer that binds 
to phosphatidylserine on the surface of activated platelets demonstrated in 
experimental aneurysms and ex vivo in human AAA thrombus samples 
following open repair75. ANX imaging may become a non-invasive tool for 
providing functional information on mural thrombus activity, which may be 
relevant to subsequent AAA growth. 
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New PET/CT tracers that are more specific are being developed. These will be 
targeted towards processes known to be important the aneurysm development 
and rupture, for example to image MMP activity or specific cellular infiltration of 
the wall, and may therefore become powerful in vivo tools to assess the 
mechanisms and progress of the disease. 
1.3.4 Functional imaging of AAA by MRI 
Nano-particles, for example ultra-small super paramagnetic iron oxide particles 
(USPIO), have a variety of applications in molecular and cellular imaging but so 
far these have not been used in human AAA imaging. USPIO enhanced MR 
imaging has been used in vivo to identify inflammation in human carotid 
plaques with increased accumulation of USPIO within macrophages76. USPIO 
may be useful as a surrogate for detecting the acute inflammatory activity 
involved in the development of abdominal aneurysms77. In a pilot study, uptake 
of USPIO in abdominal aortic aneurysms appears to distinguish those patients 
with more rapidly progressive abdominal aortic aneurysm expansion78. 
1.3.5 Measurement of aorta distensibility and compliance 
Pulse wave velocity is a measure of the time taken by the pulse pressure wave 
to travel over a specific distance of artery79. The stiffer the wall of the           
artery, the faster the wave moves. It is calculated as the distance between two 
measurement points (usually the common carotid and femoral arteries) divided 
by the time shift to the waveforms from these two points. The measurement of 
PWV is a simple, non-invasive and reproducible method to determine arterial 
stiffness79. Stiffness of the arterial wall is mainly determined by the matrix 
components of the wall, i.e., the elastin, collagen, and smooth muscle cells11. It 
is discussed above how PWV is distinct from pressure strain modulus (Table 1-
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1). A study on aneurysm specimens showed that aortic wall thickness or 
stiffness may be a better predictor of rupture for large AAAs80. 
 
Carotid femoral PWV (or aortic PWV) is considered the gold standard 
measurement of arterial stiffness79. Alternatively brachial-ankle pulse wave 
velocity (baPWV) can be measured and this provides qualitatively similar 
information as aortic PWV and is a well-established index of central arterial 
stiffness81. PWV can be measured by non-invasive methods based on pressure 
sensors82 or Doppler probes79 and MRI83 . Aortic PWV is an independent 
predictor of cardiovascular mortality in subjects older than 70years; a 1m/s 
increase in PWV increases cardiovascular mortality by 19% 84. 
The propagation of the pulse wave is inversely related to the distensibility of the 
arterial tube. In a dilated vessel the PWV is decreased and this corresponds to 
an increase in compliance.  PWV is a more easily measured property than true 
compliance, which requires an intra-arterial pressure measurement to relate to 
the corresponding change in arterial cross sectional area and this cannot be 
obtained non-invasively. Peripheral blood pressure can be used to calculate 
compliance but this underestimates the true intra-aneurysmal systolic pressure 
by 5% and overestimates diastolic blood pressure by 12%85.  
A change in pulse wave velocity along the segments of aorta may detect 
changes in local compliance that are a precursor of aneurysm formation even 
before a change in aortic diameter or other anatomical changes occur 56. In one 
small study, a high thoracic aortic compliance was related to faster growth of 
the AAA and earlier rupture86. Phase contrast MRI can also be used to measure 
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compliance in aortic aneurysms87,88. The role of PWV, distension and 
compliance measurements are yet to be validated in prediction models of AAA.  
 
MRI however is a reliable tool in AAA evaluation, 3D contrast enhanced MR 
angiography is accurate in defining the location, extent, diameter and exact 
morphology of aneurysms and the relationship to aortic branch vessels and 
surrounding structures. MRI also displays ILT as intermediate signal change on 
standard T1-weighted images but not aortic calcification. However, slow 
intraluminal flow may be difficult to differentiate from ILT. This may be over 
come with the use of spin-echo with gradient recalled echo (GRE) cine MR or 
MRA with gadolinium contrast89. Other recent MR techniques that may provide 
enhanced resolution and flow information include fast imaging employed 
steady-state acquisition (FIESTA) and balanced steady state free precession90. 
The contrast enhancement is performed on the basis of T2 to T1 ratio rather 
then inflow effects or gradient echo methods. MRI is beneficial in terms of lack 
of ionizing radiation and this specially applies to patients who are severely 
allergic to iodinated contrast media used for CT, or at a high risk of developing 
renal failure due to contrast nephropathy. MRI also provides ideal image 
modality in-terms of reproducibility with low inter-observer error for diagnosis 
and monitoring AAA expansion overtime.   
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Definitions  Measurement 
technique 
Pulse wave velocity 
(PWV)  
The velocity of the pressure wave to 
travel over a specific distance between 
two sites56,79. 
PWV = ∆x /∆t 
∆x, the distance between two recording 
sites 
∆t, the transit time between the arrival of 
pressure wave at sites 




Compliance (C) Is the fractional change in vessel cross 
sectional area divided by the change in 
distending pressure49. 
C = ∆A/∆p     
 or            
C= 1 / (PWV)2ρ           
ρ= 1055.103[kg/m3] denotes the mass 
density of blood that is assumed to be 
constant. 
Indirectly by PWV. 
 
Directly from ECG gated 
Phase Contrast MRI85, 
Tissue Doppler imaging 
(TDI)49. 
Distensibility (D) The relative change in vessel cross-
sectional area (A) that occurs during the 
cardiac cycle, divided by the 
corresponding change in blood pressure 
(∆p)50. 
D = ∆A/Ao.∆p     
Ao is minimum vessel area and ∆A 
difference in max and min area 
ECG gated CT50, 57 and 
MRI15,18, Diamove19,20  
 
Pressure strain modulus 
(Ep) 
Is a measure of the stiffness (β) or lack of 
elasticity of an artery52.                               
Ep = (Ps - Pd) [Dd / (Ds  - Dd)] 
Arterial blood pressures at peak systole 
(Ps) and end diastole (Pd) and the 
corresponding arterial diameters (Ds and 
Dd) 
ECG gated CT50 and MRI57, 
Diamove48, 52 
 
Peak wall stress The maximal force per unit area within 
the AAA wall at systolic blood pressure. 
FEA model using 3D CT 




1.4 Aims  
 
This study aimed to investigate:   
 
i) the relationship between aortic stiffness, calcification and aortic 
dilatation (aneurysm) in the population; 
 
ii) the relationship between putative biomarkers of calcification (soluble 
and microvesicle Fetuin-A levels) and calcium score measured by 
non-contrast CT in the assessment of aortic calcification; 
 
iii) the utility of a novel ultrasound-based device (AortaScan)  for 






CHAPTER 2  
Recruitment, demographics and ultrasonography  
 
 
2.1   Background 
Age and smoking are well-known factors for AAA development 94,95. 
Hypertension, hyperlipedemia (HPL), male sex, chronic obstructive pulmonary 
disease and family history are other known risk factors for AAA disease 96-99. 
AAA is less prevalent in individuals diagnosed with diabetes mellitus100. 
Atherosclerosis commonly co-exists with AAA disease; multiple studies have 
explored the theories of atherosclerosis contributing to AAA disease16,101 and 
AAA formation as pathology independent of atherosclerosis102.  
There were some differences in risk factors between our two study groups and 
whilst these were fully adjusted for, we cannot exclude the possibility that they 
may have influenced the findings. This research work forms part of larger 
ARTISTIC study programme (ARTerial Inflammation, STIffening and 
Calcification). Therefore, AAA subjects in addition to aortic stiffness analysis 
also had plaque, intima media thickness and aortic root measurements etc. 




Subjects were recruited from an established aneurysm-screening programme 
(male, aged >65 years, n=6000 invitees/year) and males already under 
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ultrasound surveillance in GSTT and KCH (n=200). All subjects underwent B-
mode ultrasound to assess for the presence of carotid or femoral plaque, 
carotid intima-media thickness (CIMT) as measures of a generalised 
vasculopathy, and confirmation of the abdominal aortic size. Aortic root 
diameter was measured. Carotid-femoral pulse wave velocity (cfPWV) was 
measured using tonometry, segmental pulse wave velocity by phase contrast 
cardiovascular magnetic resonance imaging (PC-CMR) and calcification by 
non-contrast computed tomography (CT). These investigations were completed 
on three separate visits. The aim was to recruit 50 patients with small 
aneurysms (diameter 3.0-5.5cm, n = 50) and 50 age-matched control subjects 
with normal diameter aorta to undergo tonometry, CMR, and US, non-contrast 
CT. AAA subjects and controls were identified from the aneurysm surveillance 
and screening program to form a case-control cohort.  
Male patients known to have small AAA (3.0-5.5 cm) were identified from the 
local AAA surveillance programme. Similarly male control subjects with age 
>65years were recruited from National Health Service (NHS) AAA screening 
programme. These subjects had undergone abdominal aortic ultrasound as part 
of a local AAA screening programme and were found to have a maximum aortic 
diameter <3cm. 
All subjects completed written informed consent prior to enrolment. Scans were 
performed at Guy’s and St Thomas’ NHS Foundation Trust (GSTTFT). The 
study protocols for all investigations undertaken were approved by the 





1. Patients/control subjects with a pacemaker or any inserted metal device like 
intracranial aneurysm clip, cochlear implants, which is a contraindication for 
MRI.    
2. Patients/ control subjects who had significant radiation exposure at work or in 
any other form. 
3. Patients/ control subjects who suffered from heart failure or respiratory failure 
and were unable to lie flat in scanner. 
4. Patients/ control subjects who had poor renal function (estimated glomerular 
filtration rate (eGFR) <40ml/min/1.73 m2). 
2.2.2 Demographic data and cross-sectional study  
The cross-sectional study was carried out by filling in a patient/volunteer 
registration form. A demographic data sheet was completed for each subject 
including medical history and current medications.  
2.2.3 Blood samples  
A blood sample from all patients/control subjects was taken to check 
electrolytes, renal functions (sodium, potassium, creatinine and eGFR), random 
lipid profile (cholesterol, low-density lipoproteins (LDL), high-density lipoproteins 
(HDL) and triglycerides (TGL) and circulating markers of calcification 
(microvesicle Fetuin assay).  
2.2.4 Blood pressure, carotid and femoral duplex ultrasound103 
Blood pressure      
All subjects were seated in a quiet room for at least 10 min prior to 
measurement of cfPWV. A validated oscillometric device (Omron 705CP, 
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Omron, Tokyo, Japan) was used to measure brachial blood pressure in 
duplicate. Subjects were told to fast for an hour prior to examination.  
Common carotid intima-media thickness (CIMT) measurement      
B-mode ultrasound (Siemens CV70 with 13-MHz vascular probe) was used to 
visualise left and right carotid and femoral arteries. An automated wall tracking 
software (Medical Imaging Applications, Coralville, Iowa) was used to measure 
the common carotid intima-media thickness (CIMT) in the near and far walls. 
Four measurements were obtained from both carotid arteries two of which in the 
near and two in the far wall104. The maximal measurement, of these 4 
measurements, was used for data analysis. These measurements were taken 
1-2cm proximal to the carotid bifurcation during diastole in an area free of overt 
plaque. Common carotids, carotid bifurcations, origins of the internal and 
external carotid arteries, common femoral arteries, femoral bifurcations and the 
origins of the superficial and deep femoral arteries were also examined for 
presence of plaque. Carotid plaque is defined as CIMT ≥1.5mm as suggested 
by Mannheim CIMT consensus report105. Plaque was also graded according to 
echogenicity into predominately echolucent/non-calcified (>50% of similar 
echogenicity to blood) or echogenic/calcified (>50% of similar echogenicity to 
the bright echo of the media-adventitia interface). 
2.2.5 Ultrasound of aortic root and abdomen103 
The aortic root was visualised using 2-D echocardiography from a long axis 
para-sternal view using a Siemens CV70 with 4MHz cardiac transducer and its 
diameter measured between the anterior and posterior aortic root wall at end 
diastole. The epigastrium was scanned vertically at the xiphoid process using 
the same probe in order to visualise the abdominal aorta. The diameter of the 
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abdominal aorta was measured 1-2cm below the diaphragm at end-diastole. 
AAA diameter was measured 1-2cm above the aortic bifurcation. 
2.2.6 Statistics 
Data were analysed using SPSS version 19.0 statistical software (SPSS Inc., 
Chicago, IL, USA). Primary outcome measures were cfPWV and segmental 
PWV. Differences between the control and AAA groups were analysed using 2 
tests for categorical data and unpaired t-test for continuous data. Mann-Whitney 
U test and Kruskal-Wallis test was used for non-parametric data. A P-value < 
0.05 (two sided) was considered significant.  
     
2.3 Results  
2.3.1 Recruitment 
One hundred and eighteen male subjects (aged >60 years) were recruited (AAA 
n=62; control n=56).  62 non-consecutive male patients known to have a small 
AAA (mean diameter = 3.9cm, range 3.0-5.6cm), with mean age 71years, range 
62-84 years, were recruited from the local AAA surveillance programme. 56 
male control subjects with an aortic diameter of 2.0cm, range 1.5-2.8cm, with 
mean age 66.5yrs, range 65-68 years were recruited. These subjects had 
undergone abdominal aortic ultrasound as part of a local AAA screening 
programme and were found to have maximum aortic diameter <3cm.  
Subject demographics are presented in Table 2.1 and blood results in Table 
2.2. All subjects (n=118) completed visit one, which included blood pressure 
measurement, applanation tonometry (cfPWV), ultrasound and blood tests. 
Most of the subjects completed both CT and MRI scans and some were lost to 
follow up or refused either CT or MRI after having one scan. Seven subjects 
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had a recent contrast-CT and were therefore excluded from aortic calcification 
analysis. Sixteen MRI scans were excluded from PWV analysis because of 
multiple technical reasons (Fig 2.1). 
  
 
Figure 2-1: Flow diagram showing recruitment 
Table 2-1: Subject demographics 
HTN, hypertension; HPL, hyperlipidaemia; CAD, coronary artery disease; 
PVD,vascular disease; CVA, cerebrovascular accident; COPD, chronic obstructive 
pulmonary disease; DM, diabetes mellitus; CABG, coronary artery bypass graft; BMI, 
body mass index; ACE, angiotensin converting enzyme. 







Risk factor AAA (n=62) Control (n=56)     P 
Age (years; mean  SD) 
 
  
71.5  5.7 66.4  1  0.001 
Aortic diameter [cm; mean 
(range)] 
3.9 (3-5.6) 2 (1.5-2.8)  0.001 
BMI (kg/m²; mean  SD)  27.02  4.17 25.99  3.2 0.139 
Smoking 92%(56) 53.5%(30)  0.001 
HTN 63%(39) 28%(16)  0.001 
HPL 58%(36) 28.5%(16) 0.002 
CAD 38%(24) 7.1%(4)  0.001 
PVD 27%(17) 0%(0)  0.001 
CVA 16%(10) 0%(0) 0.001 
COPD 24%(15) 1.7%(1)  0.001 
DM 24%(15) 8.9%(5) 0.030 
CABG 16%(10) 1.7%(1) 0.009 
Malignancy 24%(15) 10.7%(6) 0.090 
Aspirin 63%(39) 23.2%(13)  0.001 
Statins 74%(46) 26.7%(15)  0.001 
-blockers 29%(18) 7.1%(4) 0.027 
ACE-inhibitors 35%(22) 12.5%(7) 0.005 
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2.3.2 Blood results 
Table 2-2:Renal functions, electrolytes and random lipid profile  [mean  SD, 
unpaired t-test used except sodium and potassium (Mann-Whitney U test) 
abbreviations: LDL, low density lipoprotein; HDL, High density lipoprotein; TGL, 
triglycerides] 
 
2.3.3 Blood pressure, plaque and CIMT measurements  
All subjects had blood pressure taken in a quiet room followed by B-mode 
ultrasound to assess for the presence of carotid or femoral plaque (Table 2-3) 
and measurement of CIMT.  
Table 2-3: Blood pressure and ultrasound measurements                                  
(mean  SD, abbreviations: BP, blood pressure; MAP, mean arterial pressure) 
 
 AAA (n=62) Control (n=56)     P 
Serum creatinine (mmol/L) 
 
97.6  25.3 86.4  14.2 0.001 
eGFR (ml/min/1.73m2) 69.56  20.25 80.86  15.13 0.001 
Serum Sodium (mmol/L) 139.69  17.63 142.07  2.2 0.691 
Serum Potasium (mmol/L) 
(mmol/L)(mmol/L)(mmol/L)UNI
TS?? 
5.54  9.74 4.15  0.32 0.044 
Cholesterol (mmol/L) 4.47  1.19 4.96  1.09 0.013 
LDL (mmol/L) 2.38  1.14 2.81  1.01 0.019 
HDL (mmol/L) 1.31  0.39 1.42  0.42 0.196 
TGL (mmol/L) 1.66  1.08 1.53  0.86 0.595 
 AAA (n=62) Control (n=56)     P 
Systolic BP (mm of Hg) 138  19.1 129  15.3 0.010 
Diastolic BP (mm of Hg) 76  9.5 73  8.4 0.248 
MAP (mm of Hg) 96.6  11.8 91.1  11.2 0.151 
Heart rate (beats/min) 64  12.5 64  10.5 0.507 
Carotid plaque [%(n)] 84%(52) 55.3%(31) 0.001 
Femoral plaque [%(n)]  92%(57) 76%(43) 0.038 
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Carotid plaque is defined as CIMT ≥ 1.5 mm as suggested by Mannheim CIMT 
consensus report105. There were 6 subjects with CIMT ≥ 1.5 mm either in one or 
both arteries (AAA-n=4; Control-n= 1).  
Table 2-2: Carotid intima media thickness                                                                 
(CIMT, mm; Median (Interquartile range-IQR). (* P=0.028 AAA vs Controls) 
 CIMT 
Mean ± SD (mm) Median (IQR) 95%CI 
All Patients (n=118)  0.91± 0.20 0.87 (0.57-1.5) 0.87-0.94 
AAA            (n=62) 0.95± 0.23* 0.90 (0.57-1.5) 0.89-1.01 
Control       (n=56) 0.86± 0.15 0.83 (0.67-1.5) 0.82-0.91 
 
2.4 Discussion  
As expected AAA subjects were vasculopaths and all known risk factors for 
cardiovascular disease were common in this group.  AAA subjects had worse 
renal functions, while controls had marginally higher cholesterol and LDL level 
than AAA subjects. The latter is likely the result of the 3-fold greater numbers of 
AAA subjects using statins. AAA subjects had significantly higher systolic blood 
pressure than controls, but there was no difference in diastolic pressure and 
MAP between both groups. These findings are similar to those reported in most 
epidemiological studies except that diabetes mellitus (DM) was more common 
in our AAA group than controls9,106. There is an inverse relationship between 
the presence of AAA and DM100. Our results also show that PVD was more 
common in AAA patients than controls of the same age, a finding that is in 
keeping with others107. 
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Atherosclerosis is present in patients with AAA16 and PVD. The prevalence of 
carotid plaque in the older population is 67%108.  Our results show that the 
presence of carotid and femoral plaque was more common in AAA subjects 
than controls. Studies have suggested that presence of carotid plaque rather 
than CIMT thickness is better predictor of future CV events109-110. The mean 
CIMT values in our AAA patients and controls are similar to those reported by 
other studies patient cohorts of over 60yrs of age 111-113. CIMT in patients with 
AAA is thicker than that in the general population of a similar age, but thinner 
than patients with PVD 109,111. In our study CIMT in patients with AAA was a little 
thicker than control subjects, which is not surprising, given that as AAA subjects 
are generally vasculopaths and their mean age was higher than controls.   
The CIMT data was also divided into quartiles for analysis and comparison with 
published series114,116-117. Studies have shown that a higher CIMT quartile (Q4) 
is associated with increased CV mortality, coronary atherosclerosis and thoracic 
aortic calcification115, 116-118. Our data suggests that increasing CIMT is not 
associated with the stiffness or diameter of the aorta, which is in keeping with 
data from another study that also found no association between aortic diameter 
and CIMT quartiles in the general population116. We observed that cfPWV and 
diameter was greater in Q4 vs Q1 but this difference was not statistically 
significant. This could be a type 2 error as our CIMT data is from just 118 






CHAPTER 3  
Aortic Stiffness in presence of small AAA 
 
3.1 Background 
The aorta becomes stiff with age and this can be quantified by measuring the 
aortic pulse wave velocity (PWV). PWV is a measure of the time taken by the 
pulse pressure wave to travel over a specific distance of artery79. The more stiff 
the wall of the artery, the faster the wave moves. Aortic PWV is now known to 
be an independent predictor of cardiovascular mortality in subjects older than 
70years, with a 1m/s increase in PWV resulting in a 19% increase in 
cardiovascular mortality84. Aortic wall stiffness may also be a better predictor of 
rupture for large AAAs80. 
There are direct and indirect methods to measure aortic PWV. Carotid femoral 
PWV is considered the gold standard measurement of arterial stiffness79. PWV 
can be measured non-invasively using pressure sensors82, Doppler probes79 or 
by MRI83.  
3.1.1 Carotid-femoral pulse wave velocity (cfPWV)  
Carotid-femoral pulse wave velocity (cfPWV) or aortic PWV, the velocity of 
propagation of pressure waves over the carotid-femoral region is a simple 
robust measure of the intrinsic stiffness of the arterial wall and is emerging as 
one of the strongest predictors of stroke and myocardial infarction120-123. PWV is 
calculated as the distance between two measurement points (usually the 
common carotid and femoral arteries) divided by the time shift to the waveforms 
from these two points79. The propagation of the pulse wave is inversely related 
to the distensibility of the arterial tube. In a dilated vessel the PWV is decreased 
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and this corresponds to an increase in compliance.  PWV is more easily 
measured property than true compliance, which requires an intra-arterial 
pressure measurement to relate to the corresponding change in arterial cross 
sectional area and this cannot be obtained non-invasively. Peripheral blood 
pressure can be used to calculate compliance but this underestimates the true 
intra-aneurysmal systolic pressure by 5% and overestimates diastolic blood 
pressure by 12%85. cfPWV is measured using pressure sensors82 and Doppler 
probes79 but these modalities do not provide any information on regional aortic 
stiffness. 
3.1.2 Brachial-ankle pulse wave velocity (baPWV)  
Brachial-ankle pulse wave velocity (baPWV) can also be measured and this 
provides qualitatively similar information as aortic PWV. BaPWV is a well-
established index of central arterial stiffness81 and is measured using pressure 
sensors. 
3.1.3 Role of MRI in assessment of AAA and regional aortic stiffness 
3-Dimensional contrast-enhanced MR angiography can be used to accurately 
define the location, extent, diameter and morphology of aneurysms. MRI is an 
ideal imaging modality in terms of reproducibility, with low inter-observer error 
for diagnosis and monitoring of AAA expansion over time. Phase contrast MRI 
has been used to measure compliance in aortic aneurysms87-88 and to measure 
the PWV along aortic segments in order to investigate regional aortic stiffness83. 
This technique has not been used to investigate segmental stiffness in the 
presence of an AAA.  
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3.1.4 Aim   
To examine the relationship between AAA and aortic stiffness measured by 
cfPWV and phase contrast cardiovascular magnetic resonance imaging (PC-
CMR).  
3.2  Methods 
All subjects (Fig 3-1) underwent applanation tonometry to measure cfPWV, 
which provides a measure of total aortic stiffness. MRI was used to measure 
segmental PWV along the entire length of aorta.  
3.2.1 Carotid-femoral pulse wave velocity (cfPWV)103  
SphygmoCor system (Atcor, West Ryde, Australia; Fig 3-1) was used to obtain 
radial pulse waveforms and measurements of central arterial stiffness. These 
measurements were obtained with the subject in a supine position. Applanation 
tonometry of the radial artery with a high-fidelity transducer (Millar Instruments, 
Houston, Texas) was used to obtain an ensemble averaged radial pulse. The 
radial artery pressure waveform was calibrated to supine brachial blood 
pressure. Same device and transducer was used to calculate cfPWV from 
sequential recordings of electrocardiogram-referenced carotid and femoral 
pressure waveforms obtained by tonometry. These measurements were made 
in triplicate, and mean values were used for analysis. The path distance 
between the carotid and femoral sites was estimated from the distance between 
the sternal notch and femoral artery at the point of applanation. This reduces 
errors introduced by multiple measurements and is closer to the true path length 
than the carotid to femoral distance124. Waveforms were assessed for quality 




Fig 3-1: SphygmoCor system and screen display of cfPWV  
3.2.2 Segmental PWV using PC-CMR 
Phase contrast cardiovascular magnetic resonance imaging (PC-CMR) was 
performed on all participants using a 1.5T Achieva MR scanner (Philips 
Healthcare, Best, NL) and a 32-element receiver coil. Regional PWV was 
assessed along the 3 segments of aorta: the aortic arch between the aortic root 
and proximal thoracic descending aorta (arch/ segment-1); between the 
proximal and distal thoracic descending aorta (thoracic descending aorta/ 
segment-2); and in the abdominal segment between the diaphragm and the 
aortic bifurcation (abdominal aorta/ segment-3). PWV of the total aorta (PWV-
CMR) was calculated from the combined datasets. 
Aortic Flow measurements 
Aortic flow measurements were performed perpendicular to the aorta at 4 aortic 
levels: First flow measurement (F1), located at the level of aortic valve in 
ascending aorta; Second flow measurement (F2), at same level as F1 but in 
descending thoracic aorta; Third flow measurement (F3), at the level of 
diaphragm and fourth flow measurement (F4), just above the aortic bifurcation 
in abdominal aorta. An oblique-sagittal single-slice segmented gradient–echo 
scout image was obtained to depict the course of thoracic aorta (Fig 3-2). 
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Parameters for acquisition of scout image were flip angle =30deg, echo time 
(TE)/ repetition time (/TR) =1.3/ 4ms. Slice thickness =15mm,velocity encoding 
limit (VENC)=150cm/s. Two transverse saturation slabs were applied 
perpendicular to the aorta at the level of the aortic root and the diaphragm to 
indicate the level of the sites for subsequent through-plane velocity encoded 
magnetic resonance imaging (MRI) acquisition. One directional through-plane 
non-segmented velocity-encoded (VE) MRI using free breathing with 
retrospective ECG gating was applied perpendicular to the aorta at the levels of 
the saturation-slabs in the scout image to assess the aortic flow at the three 
measurement sites. Fourth aortic flow was obtained just above the aortic 
bifurcation. Parameters for acquisition of electrocardiographically gated flow 
sequences were FOV=220x79mm, flip angle (FA)=20deg, TE/TR=2.9/5ms. 
Slice thickness =8mm,VENC=150cm/s. The temporal resolution was 4 to 7 ms. 
2 signal averages were used and parallel imagining acceleration was not used. 
The duration of each sequence was approximately 5mins, with a total 
acquisition time of approximately 30 to 40mins.  Patient position was head first 
and supine. Once images were obtained data was analysed using a semi-
automatic cardiovascular flow-analysis software ((View Forum; Philips 
Healthcare, Best, The Netherlands). Aortic contours were detected in each slice 
location to obtain aortic flow-time curves through the cardiac cycle at the 
specified sites. 
Aortic Segment measurements 
The distance between each flow level was measured. The 2D scout image (Fig 
3-2) was used to measure segment one (arch) and segment two (descending 
thoracic aorta above diaphragm) using a curved line along the center of the 
aorta. The abdominal aortic segment was measured using a centerline plot and 
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multiplanar curved reformat (View Forum; Philips Healthcare, Best, The 
Netherlands). This three dimensional measurement of abdominal/aneurysmal 
segment was used for accuracy (Fig 3-3). 33 contiguous transverse slices 
encompassing the abdominal aorta obtained using a previously described free-
breathing ECG-triggered, dual-inversion recovery black-blood 2D zoom-imaging 
turbo spin echo (TSE) sequence125. Imaging parameters included: 33 slices, 
slice thickness = 5mm, inversion slice thickness = 8mm, FOV = = 220mm x 
67mm, spatial resolution=1x1mm, TSE factor = 25, repetition time of one 
heartbeat, shortest trigger delay ~500 ms, TE = 5ms, 120ms acquisition 
window, FA = 90°, low-high profile order, two signal averages, shortest trigger 
delay. The inversion time (TI) was set according to the Fleckenstein formula126 
to null blood. 
Segmental PWV calculation: 
The aortic flow data along with aortic segment measurements is used to obtain 
segmental pulse wave velocity using MATLAB (Release 2009b, version 7.9, 
Mathworks, Natick, MA, USA; Fig 3-4). The algorithm used to calculate PWV is 
based on arrival of ‘foot’ of pulse wave, determined by intersecting tangent 
method127.  
PWV (m/sec) was calculated as: 
vt = [d1 + d2 + d3] ÷ [d1/v1 + d2/v2 + d3/v3] (m/s) 
(where dx is the aortic path length between the measurement sites and vx the 









Fig 3-3: Multi-planar reconstruction (MPR) was used to measure abdominal/aneurysmal 
segment of aorta. 
 
3.2.3 Statistics 
Data were analysed using SPSS version 19.0 statistical software (SPSS Inc., 
Chicago, IL, USA) and Winbugs version 1.4.3. Primary outcome measures were 
cfPWV and segmental PWV. Unpaired t-test was used to compare PWV 
between groups. One-way ANOVA (Bonferroni correction) and paired t-test was 
used when comparing PWV along the segments within a group. Wilcoxon 
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signed-rank, Mann-Whitney U and Kruskal-Wallis tests were used for non-
parametric data. A P-value < 0.05 (two sided) was considered significant. 
Pearson’s correlation was used for parametric data and Spearman’s for non-
parametric data. Correlation and Bland- Altman plot128 was used to test for 
agreement between PWV measured by tonometry and CMR. Stepwise multiple 
linear regression models were used to examine association between cfPWV 
and other known risk factors of cardiovascular disease (listed in table-2-1, 2-2 
and 2-3). The significance level for variable entry into the model was a P value 
< 0.1. Binary logistic models were used to test associations between AAA 
disease and other risk factors including cfPWV. 
WinBugs was used to calculate AAA growth rate and examine its relationship 
with cfPWV and mean arterial pressure (MAP). Markov Chain Monte Carlo 
(MCMC) methods were implemented using WinBugs and used to fit random 
effects growth models to the data. First, a linear growth rate was assumed, and 
then a quadratic model fitted and models compared using the Deviance 
Information Criteria. As the quadratic model was not significantly better the 
linear model was used. The intercept and growth terms were assumed to follow 
a normal distribution and non-informative priors were used. Posterior 
distributions were generated using 20000 MCMC samples after a run in of 
10000. Average growth rate was determined using the median of the posterior 
distribution of the linear component of the model and is presented with the 
corresponding 95% Confidence interval (CI).   
First models were fit to the data without covariates and average annual growth 
rate calculated. Baseline AAA size, MAP and cfPWV were then added as fixed 
terms and the influence of each on annual growth rate assessed by examining 




3.3.1 Carotid-femoral pulse wave velocity (cfPWV) 
cfPWV was measured in 62 AAA patients and 56 controls using tonometry. 
cfPWV  was significantly increased in subjects with AAA compared with controls 
(mean±SEM, 12.9±0.39 vs 10.8±0.29, m/sec respectively,  P0.0001; Fig 3-4 ).  
 
Fig 3-4: cfPWV (mean±SEM) was significantly increased in subjects with AAA 
compared with controls (unpaired t-test) 
  
3.3.2 Correlation of carotid-femoral pulse wave velocity (cfPWV) and aortic 
diameter 
There was a significant weak correlation between cfPWV and aortic diameter 
when analysing data from all subjects (Table 3-1; Fig 3-5), but no correlation 
between these parameters when analysing AAA and control groups separately. 
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There was no correlation in AAA diameter and PWV in aneurysmal segments 
measured by CMR .  
 








Fig 3-5: Correlation between cfPWV and diameter  (n=118; r=0.295, P=0.001) 
 
3.3.1 Regression analysis 
As the AAA and control groups were not matched for age (which would affect 
PWV) we carried out regression analysis. 
 Pearson r P 
AAA patients (n=62) -0.119 0.355 
Control subjects (n=56) -0.055 0.688 
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Multivariate regression model  Linear regression was used to determine 
whether there was an association between cfPWV and AAA, independent of the 
known risk factors for cardiovascular disease (listed in Table 2-1, Table 2-2 and 
Table 2-3). The significance level for variable entry into the model was a P<0.1. 
Multivariate regression analysis showed that only AAA disease, (B=1.47, 
P=0.033),) and heart rate (B=0.05, P=0.018; Table3-2) were independently 
correlated with cfPWV. 
Table 3-2: Linear regression analysis of the relationship between cfPWV and AAA  
R2=0.51. Total number of subjects, n=118. Variables entered in the model include: age, 
HTN, diastolic blood pressure, MAP, AAA (y/n), smoking, HPL, COPD, CAD, CVA, 
CABG, Cholesterol, LDL, HDL, TGL, ACEI, Statins, anti-platelets, b-blockers, presence 
of carotid and femoral plaque, heart rate, major surgery, malignancy (abbreviations as 






Logistic regression analysis  In order to determine the best predictor of the 
presence of an AAA the data was reanalysed using logistic regression.  This 
revealed that cfPWV, age and mean arterial pressure were independent 
predictors of the presence of an AAA (Table 3-3); with the probability of having 
AAA increases 3.1-fold for every 1m/s increase in cfPWV, 2.7fold for every one 







Lower 95%CI Upper 95%CI P Value 
 AAA (y/n) 1.39 0.004 2.781                                                                                                                                                                                                                                                                  0.049
Heart rate (HR) 0.05 0.006 0.096 0.028 
MAP 0.12 0.045 0.194 0.002 
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Table 3-3: Logistic regression analysis summary 
 R2= 0.852, 0.63 (Cox and Snell). Model 2 (1)=119.95, P<0.0001. Variables entered: 
Age, smoking, cfPWV, HTN, HPL, DM, COPD,CAD, systolic BP, diastolic BP, MAP, 
Aspirin, b-blockers, statins, cholesterol, LDL, HDL, TGL, PVD, CVA, CABG, carotid 
plaque, femoral plaque, heart rate, major surgery, malignancy (abbreviations as in 










cfPWV 1.14 (0.56) 3.1 1.04 .51 0.042 
Age 1.00 (0.41) 2.7 1.21 6.16 0.015 
MAP 0.33 (0.15) 1.3 1.03 1.88 0.030 
 
3.3.2 AAA growth rate and cfPWV  
The mean baseline size of AAA was 3.9 cm (3-5.6 cm) and the mean growth 
rate was 1.2mm/year.  Ultrasound measurements of diameter were used to 
calculate AAA growth rate (Fig 3-6).  The growth rate of AAAs was related to 
their initial size (with larger AAA having a faster growth rate). There was no 
evidence of a relationship between AAA growth rate and cfPWV or MAP.  
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Fig 3-6: A linear growth was observed in AAA (n=62) 
 
3.3.5 PWV measurement using phase contrast cardiovascular magnetic 
resonance imaging (CMR-PWV) 
CMR-PWV (meanSEM) was measured along 3 segments of aorta (arch, 
thoracic descending aorta and abdominal aorta) in 88 subjects (n=46 AAA and 
n=42 controls). The mean age of AAA patients was 71.3  5.7 and controls was 
66.3  1 years. PWV was significantly increased in subjects with AAA compared 
with controls (10.03±0.30 vs 8.4±0.24m/s, respectively, P0.0001, Fig 3-7).  
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Fig 3-7: CMR-PWV along the entire aorta was significantly higher in subjects with 
AAA 
 
3.3.6 Agreement between PWV measured by tonometry and MRI 
There was a significant positive but fair correlation between PWV measured by 
tonometry and MRI (r=0.519; n=88, P0.0001; Fig 3-8A). The mean (±SD) PWV 
measured by MRI (9.2 ± 2m/s) was, however, significantly lower than that 
measured by tonometry (11.8 ± 2.9m/s; P 0.0001). Bland Altman analysis 
shows a poor agreement between both methods. From the graph we observe 






Fig 3-8: (A) Correlation (Pearson) between PWV measured by tonometry (cfPWV) 
and MRI (PWV-CMR). (B) Corresponding Bland-Altman plot showing agreement 
between the two methods.  
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3.3.7 Segmental CMR-PWV measurement  
Segmental aortic pulse wave velocity in AAA patients  
There were no significant differences in PWV (Fig 3-9; one-way ANOVA; P= 
0.640) along the three aortic segments of AAA subjects (Table 3-4; paired t-
test). 
Table 3-4: Comparison of segmental PWV in AAA subjects (n=46).  




Arch vs thoracic descending aorta 9.70.56   vs    10.10.59 0.635 
Arch vs abdominal aorta 9.70.56   vs    10.60.48 0.222 
Thoracic descending aorta vs abdominal 
aorta 
10.10.59 vs    10.60.48 0.525 





Fig 3-9: There is no change in PWV along the segments of aorta in AAA subjects 
(n=46; one-way ANOVA; P=0.640)  
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Segmental aortic pulse wave velocity in control subjects     
The abdominal aorta in control subjects is stiffer than the thoracic aorta in the 
same subject (Table 3-5; paired t-test, Fig 3-10; one-way ANOVA). 
 
Table 3-5: Comparison of segmental PWV in control subjects (n=42) 
Segmental comparison (Control) PWV (m/s)  
mean SEM 
P  
Arch vs thoracic descending aorta 8.1  0.41 vs 8.0  0.64 0.875 
Arch vs abdominal aorta 8.1  0.41 vs 10.0  0.51 0.010 
Thoracic descending aorta vs abdominal aorta 8.0  0.64 vs 10.0  0.51 0.029 
Thoracic aorta vs abdominal aorta 8.1  0.39 vs 10.0  0.51 0.008 
 
 
Fig 3-10: PWV is greater in abdominal segment vs thoracic segment of aorta in 
control subjects (n=42; one-way ANOVA; P=0.012) 
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Comparison of segmental CMR-PWV between AAA and control 
CMR-PWV showed that the arch and descending thoracic segments were stiffer 
in AAA patients compared with control subjects (P=0.002, Table 3-6); but no 
difference was found in the abdominal segment (P=0.396).  
Table 3-6: Comparison of segmental PWV between AAA subjects and controls 
 
3.3.8 Correlation of between pulse wave velocity and aortic diameter 
Overall there was a weak correlation (r=0.338, P=0.001) between total CMR-
PWV and aortic diameter (Fig 3.7), but this correlation disappeared when the 
AAA and control groups were separated. There was no correlation between 
AAA diameter and PWV in the aneurysmal segment measured by CMR (Table 
3-6). PWV is expected to decrease with increasing diameter of conduit but this 
phenomenon was not observed in subjects with AAA.  




PWV1 (arch) 9.7  0.56 8.1  0.41 0.027 
 
 
PWV2 (thoracic descending aorta) 10.1  0.59 8.0  0.64 0.017 
PWV- Total Thoracic (PWV1+2) 9.9  0.38 8.1  0.37 0.002 
PWV3 (abdominal aorta) 10.6  0.48 10.0  0.51 0.396 
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Table 3-7: Correlation between PWV and diameter abdominal aorta/aneurysm 
 
 Pearson r P 
cfPWV vs diameter (n=118) 0.295 0.001 
cfPWV vs AAA diameter (n=62) -0.119 0.355 
cfPWV vs control diameter (n=56) -0.055 0.688 
CMR-PWV vs diameter (n=88) 0.338 0.001 





Total aortic stiffness, measured by cfPWV, is an independent predictor of 
cardiovascular events and is known to increase with age, while the two best-
known risk factors for AAA disease are age and male sex. We measured aortic 
stiffness (cfPWV) using tonometry in men above the age of 65. Our results 
show that subjects with AAA have a stiffer whole aorta than normal men of the 
same age, which is not unexpected as AAA subjects have a greater vascular 
disease burden. The likelihood of AAA being present increases 3.1-fold for 
every 1m/sec increase in cfPWV.  
We also used MRI129 to measure aortic stiffness in AAA and control subjects. 
The application of CMR-PWV has also allowed the assessment of regional 
changes in aortic stiffness. We found that thoracic aorta was stiffer in AAA 
patients, and the relatively higher stiffness of the abdominal aorta found in 
people with normal diameter aortas is lost in patients with AAA.  
Tonometry and CMR have been both validated to measure total aortic stiffness 
84, 121-123 and CMR has been used to measure segmental stiffness. We used 
both methods to measure aortic stiffness and observed fair agreement between 
methods as described previously130. Our finding that that PWV in the abdominal 
segment was increased in subjects with normal sized aortas is in agreement 
with previous studies, when measured by either MRI83,130 or invasive catheter 
131.  
We did not find any correlation between aneurysm diameter and PWV of 
aneurysmal segment. We also carried out a linear regression and this showed 
that thoracic PWV is significantly and positively correlated to abdominal aortic 
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diameter and systolic blood pressure. It has been shown that age related 
increase in aortic diameter and tortuosity occurs in thoracic aorta particularly 
aortic arch130.   
Age can cause changes in regional aortic stiffness and is most strongly 
associated with a stiffer abdominal segment83. We found the same in our 
control group (men with a mean age of 66.5years). Measurement of segmental 
aortic stiffness by CMR along 3 segments of the aorta in our study is in 
agreement with the reported work83,130. Our use of this technique in assessing 
segmental aortic stiffness in patients with AAA revealed that this cohort had a 
stiffer thoracic aorta than controls.  There was no difference in the stiffness of 
the aneurysmal segment in AAA compared with the abdominal segment in 
control subjects. Regression analysis of the cfPWV and thoracic CMR-PWV 
shows that both are associated with AAA, independent of any other risk factor.  
AAA growth rate in our group was 1.2mm/year, while others have reported the 
AAA diameter increases of 3mm/year132. Our analysis suggests that there is no 
relationship between cfPWV and growth rate of AAA. However, this analysis is 
retrospective and limited by the small numbers (62 patients) and firm 
conclusions regarding this relationship cannot be drawn. 
Only a few studies have measured PWV in patients AAA. In one study following 
infra-renal AAA repair; PWV in descending thoracic aorta was measured using 
Doppler echocardiography. Their results suggested that subjects with ruptured 
AAA had a low PWV (high compliance) in the thoracic aorta 86.  They postulated 
that high thoracic aortic PWV (low compliance) prevented AAA from rupture. 
They also concluded that a higher thoracic compliance might be related to 
faster growth of the AAA and earlier rupture. In another study total PWV was 
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measured in large aneurysm with tonometry before and after surgical repair and 
again finding an increase in PWV post-operatively when a graft is in place133.  
The stiffness of aortic wall samples taken at operation has also been related to 
the risk of rupture of large AAA 80. Thoracic aortic stiffness may be of prognostic 
value for the occurrence of aortic dilation or aneurysm. 
Pulse wave imaging technique134,135 using B-mode ultrasound has been used to 
measure aortic or aneurysm PWV in humans and mice. PWV was measured 
initially in an elderly subject with AAA and it was no surprise that it was higher 
than young healthy volunteers. The same technique was also used to show 
differences in pulse wave propagation in normal, sham and Ang-II treated 
aortas of mice56. The pulse wave moved significantly non-uniformly in Ang-II 
treated aortas, but there was no difference in PWV between sham and Ang-II 
treated aortas.   
The most significant findings of the present study are that patients with AAA 
have a significantly stiffer aorta and this is accounted for by an increase in 
thoracic aortic stiffness. The normal ratio of relatively higher abdominal segment 
stiffness found in control subjects, however, is lost in patients with AAA. 
Patients with aneurysms have therefore a generalised increase in stiffness but 
with a localised loss of stiffness associated with the dilated segment.  
An expert consensus document on arterial stiffness has suggested that “a 
change in pulse wave velocity along segments of the aorta may detect changes 
in local compliance that are a precursor to AAA formation before a change in 
aortic diameter is detected”79. Our study is the first to measure and compare 
aortic stiffness (PWV) in patients with AAA and normal aorta. The data that we 
present add further support to the notion that patients with AAA have a stiffer 
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abdominal aorta prior to development of an aneurysm. This leads us to 
speculate that aneurysm development may be a remodeling response aimed at 








         Calcification of the arterial wall is a marker of atherosclerosis136 and is 
more common in patients with hypertension, diabetes mellitus and renal 
failure137. It has been extensively quantified in coronary and carotid beds to 
predict CV morbidity and mortality116,138-139. It is also a major factor contributing 
to arterial stiffening140,141. Abdominal aortic calcification is also an independent 
predictor of subsequent vascular morbidity and mortality142. Calcium score 
provides an accurate estimation of the coronary atherosclerotic burden and is 
powerful predictor of cardiac events in asymptomatic patients. CT Calcium 
scoring is an established tool for initial risk assessment, but has currently limited 
value as an endpoint in serial progression/regression trials143. Atherosclerosis 
and arterial stiffness has a modest correlation144.  
Autopsy analysis shows that 82% of AAA ruptures occur at the posterior 
surface, where there is focal elevated stress and where there is most 
calcification38. There is evidence that a calcified aneurysm has a 3-times 
increased risk of rupture than a non calcified aneurysm145.  
4.1.1 Calcium scoring systems   
There are a number of scoring systems for measuring the calcium burden in the 
vasculature. Most methods were developed to score calcium in coronary 
arteries using electron beam CT images. The Agatston calcium score146 is the 
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most commonly used and validated system, that scores calcium levels using CT 
images. Score obtained by this method is also called traditional calcium score 
(TCC). In this method computer software multiplies the area of calcification with 
an assigned coefficient selected on the basis of the highest attenuation 
measured in the area. However, this system has its limitations. There are 
problems with noise artefacts and variations in the scanning protocol, which can 
lead to variations in reproducibility147.  The other commonly used scoring 
system is ‘ calcium volumetric score’ (CVS) and has excellent reproducibility148. 
This system is based on a value that represents volume calculated with 
isotropic interpolation technique149.  Aortic calcification has also been measured 
using lateral lumbar radiographs and calcium quantified using a validated rating 
scale142. Another method that uses FDG-PET and CT, describes a combined 
scoring system, which divides patients in 4-groups on the basis of presence of 
calcification and uptake in the thoracic aorta68.  
Vascular calcification  
Calcium apatite is the type of calcium crystal that mostly accumulates in the 
blood vessel wall26. Vascular calcification is a complex mechanism involving 
deranged mineral and lipid metabolism, inflammation, apoptosis, osteogenesis 
and matrix degradation. Calcification mechanisms have similarities with 
mechanism of bone formation150. It has been suggested that main target of 
calcification is vascular smooth muscle cells (VSMCs)151. Some known 
circulating inhibitors of calcification include fetuin-A, matrix-GLA-protein (MGP) 
and osteoprotegrin/rank ligand (OPG/RANKL). Vascular calcification is 
regulated by osteogenic agents (fetuin-A, MGP, OPG and RANKL) released by 
microparticles in response to mechanical and cytokine-induced stress29.   
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Fetuin-A promotes anti-apoptic activity in VSMCs152. Inhibitors, including OPG, 
are present in VSMC derived micro-particles (VSMMPs) and are thought to play 
a key role in matrix degradation and calcification. Increased circulating OPG 
has been weakly associated with aneurysm progression in man32. In this study 
we chose to measure fetuin-A as a biomarker of calcification. This protein  
(originally known as alpha2-Heremans Schmid glycoprotein; AHSG) is a liver-
derived partially phosphorylated glycoprotein that circulates at about 700mg/l 
and acts as a mineral chaperone that mediates mineral transport from the 
extracellular space and general circulation153. A fraction of the total circulating 
fetuin-A interacts with insoluble mineral nuclei to form soluble colloidal 
calciprotein particles (CPP), preventing calcium crystal deposition154.  It has 
been shown that low serum levels of fetuin-A have associations with raised C-
reactive protein (CRP)155 and cardiovascular death156. Fetuin-A inhibits 
calcification of blood vessels30,157 and has anti-inflammatory properties158. 
Increased aortic valvular calcification is associated with low fetuin-A levels in 
serum159. 
Vascular calcification is a regulated process that involves deposition of 
osteoblast-like cells in vessel wall and loss of inhibitors of mineralization or 
biomarkers of calcification like OPG, MGP and Fetuin-A28. Although the 
relationship between circulating biomarkers of calcification and aortic 
calcification on imaging has yet to be defined, there is evidence to show that 
low circulating fetuin-A levels are associated with greater aortic calcification160.  
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Aims  
(i) To quantify and compare aortic calcification in AAA and control groups using 
non-contrast CT.  
(ii) To study the relationship between aortic calcification and stiffness (PWV). 
(ii) To investigate the relationship between aortic calcification (CT) and 
circulating fetuin-A levels 
4.2 Methods    
4.2.1 Calcification measurement using non-contrast CT 
Non-contrast enhanced images were obtained on a 16-slice helical scanner with 
a 3mm slice thickness (Brilliance CT, Philips, Eindhoven, Netherlands). Osirix 
imaging software version 3.9 was used to measure the calcification (Electron 
beam, voxel threshold  130HU; Fig 4-1). The volume method of calcium 
scoring161 included in system software was used to measure calcium burden in 
the aorta. The volume of the wall occupied by calcium deposits (CVS) is a 
validated, accurate technique162 and has excellent repeatability148,161. Areas of 
>1mm2 calcium in one or more slices of aorta (voxel volume X number of voxels 
in region of interest) were summated. The calcium was measured from the 
aortic valve to just above aortic bifurcation in every slice. Anatomical landmarks 
were used on CT and CMR to divide aorta into three segments (arch, thoracic 
descending aorta and abdominal aorta) as for PWV-CMR. The slice thickness 
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was increased to 5mm for quantification of calcium. 
 
Fig 4-1: Transverse section of abdomen illustrating calcium in the aortic wall (A). Calcium 
coloured red after use of calcium scoring tool (B) 
 
AAA diameter measurement: 
AAA was measured on CT scan (anterior to posterior) for all subjects who had 
segmental PWV analysis. However, if a patient was lost to follow up prior to CT 
scan then ultrasound diameter measurement was used (regression models).  
Biomarker analysis 
Citrated blood samples were collected at recruitment (n=118) and plasma 
obtained following centrifuging (1500g) for 15min within 1hr of collection. The 
plasma was aliquoted and stored at -20oC. FetuinA analysis (free and VSMPP-
associated) was carried out by one of our collaborators (Prof Catherine 
Shanahan, KCL). This method is currently undergoing a patent application. 
Aortic calcification was quantified on non-contrast CT (n=77).  
4.2.2  Statistics 
Data were analysed using SPSS version 19.0 statistical software (SPSS Inc., 
Chicago, IL, USA).  Wilcoxon signed-rank, Mann-Whitney U or Kruskal-Wallis 
tests were used for non-parametric data. A P-value < 0.05 (two sided) was 
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considered significant. Pearson’s correlation was used for parametric data and 
Spearman’s for non-parametric data.  
4.3 Results 
4.3.1 Aortic calcification in AAA and control subjects 
Aorta in AAA subjects was heavily calcified in comparison to control subjects 
(Fig 4-2; P  0.0001). Calcification data was skewed, and therefore reported as 
median (interquartile range-IQR).  Calcification of the entire aorta in AAA (n=39, 
710.86 years) and control subjects (n=38, 660.17 years) from aortic valve to 
just above bifurcation was 6.690.88 (range 0.01-26.25) and 1.3810.31cm3 
(range 0-8.96cm3) respectively. Comparison of segmental aortic calcification 








Table 4-1: Comparison of segmental and total aortic calcification in AAA and 
control aortas (median and IQR; Mann-Whitney U test and Kruskal-Wallis test). 
 
4.3.2 Aortic calcification along the aortic segments 
There was a significantly greater amount of calcium present in the segments of 
aortae of patients with AAA than in the corresponding segment in the control 
aortae, although the pattern of calcium deposition along the aorta was similar in 
both groups (Table 4-1). The thoracic descending aorta was least calcified 
whereas abdominal aorta was most calcified, with arch calcification 2-fold 
higher than in the thoracic descending aorta, but ~6-fold less than in the 
abdominal aorta (Fig 4-3; Fig 4-4). 
 
 Aortic calcification (cm3) 
 




    P 
Entire aorta (median/IQR) 6.28 (2.05-10.15) 0.675 (0.228-1.3)  0.001 
Arch  0.736 (0.322-1.687) 0.078 (0.001-0.271)  0.001 
Thoracic descending aorta 0.318 (0.009-1.036) 0.000 (0-0.045)  0.001 
Abdominal aorta 4.233 (1.459-6.987) 0.494 (0.157-0.987)  0.001 
Thoracic (arch+ thoracic 
descending aorta) 




Fig 4-3: Distribution of calcium along the aorta in AAA subjects (n=39).  







Fig 4-4: Distribution of calcium along the aorta in control subjects (n=38). The 
abdominal aorta has significantly higher calcium content than total thoracic aorta 
(P=0.0001).  
 
4.3.3 Relationship between calcification and aortic stiffness (PWV)  
77 subjects completed both non-contrast CT and CMR.  In AAA patients 
(710.86 years), calcium deposition correlated with PWV in the entire aorta 
(R=0.45, P<0.0001; Fig 4-5) and the thoracic segment (R=0.45, P=0.004), but 
not in the abdominal segment (Table 4-2). Correlation of segmental PWV with 
calcium score was also done separately for both groups but no correlation was 
found except in thoracic aorta of AAA subjects (Table 4-2).  
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Fig 4-5: Correlation between aortic PWV and calcium (normal log transformation) 
in whole aorta of both AAA and control subjects (n=77; Spearman’s r 0.451; P  
0.0001) 
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Table 4-2: Correlation between PWV and calcium score (n=77) [AAA (n=39; 
710.86 years) and control subjects (n=38; 660.17 years)]. Significant correlation is 
marked with *. 
Control, 
 n=38 
Spearman’s r P value 
Arch  0.167 0.317 
Thoracic descending aorta 0.193 0.245 
Thoracic aorta (arch + thoracic descending aorta) 0.159 0.340 
Abdominal aorta 0.067 0.690 
AAA,   
n=39 
  
Arch  0.303 0.061 
Thoracic descending aorta 0.341 0.033* 
Thoracic aorta (arch + thoracic descending aorta) 0.453 0.004* 
Abdominal aorta 0.065 0.696 
Entire aorta 0.262 0.107 
AAA + Controls  
n=77 
  
Thoracic aorta 0.422  0.001* 
Abdominal aorta 0.169 0.143 
 Entire Aorta 0.451  0.001* 




4.3.4 Fetuin-A analysis 
Fetuin-A concentration in vesicle and plasma was measured in 35 subjects who 
had a matching calcium score and from which there was sufficient sample 
volume for analysis.  Nine subjects were excluded because of inadequate 
sample volume (n=7) and no CT available for calcium quantification (n=2). The 
mean (SD) vesicular fetuin-A concentration and levels in plasma were 3.8  
3.0mg/l and 1304570mg/l respectively. We found weak inverse correlations 
between both vesicle (Spearman’s r = -0.459; P= 0.018) and plasma fetuin-A 
(Spearman’s r = -0.562; P= 0.003) concentration and CT calcium score (Fig 4-6; 
Fig 4-7). No correlation was observed between aortic stiffness (cfPWV) and 
fetuin-A concentration in vesicle (r=143; P=0.486) or plasma (r=0.035; P= 
0.864). There was no difference in fetuin-A concentration in AAA and control 
subjects (Table-4-3). 
 




Fig 4-7: Correlation between CT calcium score and plasma fetuin-A 
concentration 
 
Table 4-3: Vesicle and plasma fetuin-A concentration in AAA and controls.  
The levels of both free plasma and bound (vesicle) forms of fetuin-A were similar in 
both groups (P>0.10, unpaired t test)  
 
 Fetuin-A concentration  
(mg/l, mean  SD) 
Fetuin-A source AAA (n=17) Control (n=9) P value 
Plasma  1218  623 1465. 437 0.303 






Our objective was to explore the relationship between segmental aortic stiffness 
and regional aortic calcification. We used the same segmental division for CT 
analysis as used for MRI scanning to measure PWV (Chapter-3). Calcification 
was significantly greater in the entire aortae of AAA patients than those of 
control subjects, with the abdominal segment most calcified in both groups. 
There was a significant correlation between aortic stiffness and aortic 
calcification (as measured by CMR-PWV and CT-scan respectively) when the 
entire aorta in both AAA and control cohorts was analysed. This correlation 
was, however, lost in the abdominal segment and was found only in the thoracic 
segment when the AAA and control subjects were analysed independently.  
Segmental correlations have been observed in healthy subjects (average age 
65years) in previous studies163, but the strength of the relationship was poor in 
the ascending aorta and described as only ‘fair’ in both the descending thoracic 
and abdominal aorta.  
CT analysis of calcification in patients with chronic kidney disease shows a 
relationship between abdominal aortic calcification and aortic stiffness164-165. 
Comparison of our results with other studies, such as these, is however, difficult 
as pathology may vary, the methods chosen in some studies are subjective, 
and the segmental division of aorta may also be different.  There is no standard 
classification scheme for scoring aortic calcification,166 with a variety of ways 
being described142,148. Our data shows that most calcium is deposited in the 
abdominal aorta in both healthy and aneurysmal aortas. We have also shown 
that the abdominal aorta is stiffer in healthy controls than thoracic aorta 
(Chapter-3). We did not, however, find any segmental correlation between 
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calcification and stiffness in abdominal aorta (Table-4-2), which suggests that 
although calcification may contribute to aortic stiffness, it may not be the only 
factor responsible for stiffness22.  
The mean plasma fetuin-A concentration is in the subjects assessed for calcium 
score in this study were almost 2-fold higher than those previously reported in 
the normal population (0.7g/l)153. One reason for this could be that our group 
includes men above the age of 65. The fetuin-A level were the same in both 
AAA and control groups. I can find no evidence from the literature to show how 
serum fetuin-A levels fluctuates with age.  
There was a significant inverse relationship between plasma fetuin-A levels and 
aortic calcification measured on CT from aortic root to bifurcation in our study. 
This was not replicated when assessing the correlation between vesicular 
fetuin-A. A similar inverse relationship between plasma fetuin-A and aortic 
calcification has been reported, but the calcified area of abdominal aorta was 
measured only at the level of L3 and L4 from CT160. Similarly in another study 
non-vesicular fetuin-A negatively correlated with coronary artery calcification 
scores (CACS), however there was an absence of correlation between serum 
fetuin-A and CACS167. Experiments in animal models have shown that fetuin-A 
deficient mice develop micro-calcifications168. 
We did not find a correlation between aortic stiffness (cfPWV) and fetuin-A 
levels. Our study was, however, limited by small number of subjects who had 
fetuin-A analysis performed. In a larger study (n=185) increased phosphorylated 




CHAPTER 5  
AAA imaging using FDG-PET/CT 
 
5.1 Background 
PET offers the possibility of using radiotracers to image functional activity in the 
wall of the aorta. Currently one of the tracers with clinical application is the 
glucose analogue 18-fluorine (18F) flurodeoxyglucose (FDG). It enables 
detection of increased glucose metabolism. Increased uptake is characteristic of 
many cancers and other non-malignant processes such as infection and 
inflammation68. It could therefore potentially assess the metabolic activity in the 
aneurysmal wall69. FDG uptake is expressed as standardized uptake values 
(SUV), for tissue attenuation. The SUV is calculated either pixel-wise or over a 
region of interest for each image.  
Atherosclerosis is more prevalent in abdominal aorta and in combination with 
PET/CT, segmental measures of PWV will distinguish between stiffening 
associated with different patterns of calcification in the thoracic and abdominal 
aorta. The pattern of calcification and co-localisation with metabolically active 
plaque will determine whether calcification is likely to be primary or secondary 
to atherosclerosis.  
5.2 Methods:  
The scan consisted of scout CT, attenuation correction CT scan, non-contrast 
enhanced CT and 3 dimensional FDG scan. PET/CT fusion images (Fig 5-1) 
were used to co-register calcification with aortic wall metabolic activity. These 
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PET-CT fusion images68 were scored for tracer uptake and enhancement. FDG 
uptake on PET/CT images was co-related with measures of plaque burden 
quantified on CMR. (REC reference: 10/H0802/89) 
5.2.1  FDG-PET/ CT scan  
The scans were acquired using a Discovery volume PET/CT scanner (VCT ; 
General Electronics Health Care). As with PET scans performed for 
investigating oncological, inflammatory and infectious processes, the patients 
were starved for at least 6 hours prior to the scan. This is to minimise 
background uptake from the gastrointestinal track that would obscure the 
abdominal aortic 18F-FDG uptake. An intravenous injection of 300 to 400 MBq 
of 18F-FDG is administered through an indwelling catheter. The patient is sat in 
a quiet injection room during the subsequent 60-min of 18F-FDG uptake phase, 
before the acquisition of the scan. This is normally 90 minutes for oncological 
studies but was reduced for vascular imaging as optimal signal to background 
uptake. Images are then acquired with an emission scan photons collected from 
the patient) and transmission scan (using an external gamma source). We 
performed a classical acquisition from the aortic arch to the femoral heads over 
30minutes. The effective radiation dose being 0.025mSev/MBq. The sequences 
were recorded at each couch position for 3 minutes. Coronal, sagittal and 
transaxial images were based on ordered subset expectation maximisation 
iterative reconstruction algorithm with post-injection segmented attenuation.  
The CT scan was carried out of the arch, thoracic and abdominal aorta (CT-
parameters used are outlined in Appendix 8.1).  A scout CT scan is performed 
with helical CT from the region of interest namely arch to femoral heads. 
Following the PET scan a non-contrast CT is performed. The patient setup was 
head first, supine, wedge under the knees and arms were placed above the 
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patient’s head for CT acquisitions (arms down if patient was unable to raise).  
5.2.2 FDG-PET/CT Image Processing 
Co-registration was carried out at a Hermes workstation (HERMES Medical 
Solutions Inc. Canada).  
5.2.3 FDG-PET/CT Image analysis 
A sub set of patients (n=10) had 18-F FDG-PET/CT scan. PET/CT was used to 
identify calcification and metabolically active atheromatous plaque using FDG 
as a marker170. Images were analysed using Osirix imaging software version 
3.9. The areas of most intense aortic wall 18F-FDG uptake were identified on 
each slice during a slice-by-slice analysis and regions of interests were drawn 
(ROIs) over the aortic wall and lumen. The maximum activity concentration for 
each region was recorded. For each period of dynamic PET imaging, the mean 
maximum activity concentration (that is corrected for decay) was recorded and 
used to determine maximum standardised uptake value (SUVmax) that was in 
turn normalised to body weight of the patient. This is calculated using the 
formula below: 
 ROI decay – corrected activity (kBq/ tissue (mL) 
SUV  = _______________________________________ 
Injected 18F-FDG dose (kBq/body weight (g) 
The associated standard error (SE) (SD/√4) was calculated. This calculation is 
repeated in the patients to ensure that the mean SUVmax for the aortic wall and 
the lumen and the target-to-background (TBR) ratio is calculated. Standardised 
uptake values (SUVs) > 2 for all regions of FDG uptake within aortic lumen and 
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wall was considered significant (Fig 5-2). SUVmax of liver and blood was 
measured.  
5.3 Results 
Eleven subjects had 18-F FDG-PET/CT scan. One subject was excluded from 
analysis because he failed to have a CMR (excluded due to suspicion of metal 
inside body) for plaque imaging. The mean AAA diameter was 4.24 cm (3-5.6). 
The SUVmax was 2.617 and 1.865 in liver and blood respectively. Abdominal 
aorta was divided into two segments aneurysmal and normal aorta. FDG-PET 
uptake (> 2 SUVmax) was seen in the aneurysmal lumen and normal aortic 
segment of 50% (n=5) patients. Only two subjects (20%) showed an uptake of 
FDG (> 2 SUVmax) within the aneurysm wall (Fig 5.1 and 5.2). The wall of 
normal aorta did not show an uptake > 2 SUVmax. There was no correlation 
between plaque burden, aortic calcification and FDG uptake.  
 
Fig 5-1: Fused PET/CT  
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Fig 5-2: Image showing a FDG uptake of  > 2SUVmax   
 
5.4 Discussion 
The mean AAA diameter of this small sub-group (n=10) that underwent PET/CT 
was 4.24 cm (3-5.6). In one study the mean SUVmax of patent vessel has been 
reported 1.9 171. In our group of subjects the mean SUVmax of blood within 
aorta was 1.86. Only five subjects (50%) had FDG uptake >2 SUVmax in 
aneurysm lumen and similarly four had uptake in the lumen of non-aneurysmal 
aorta. FDG-uptake of  >2 SUVmax was observed in the aneurysm wall of only 
two subjects. Our results are in agreement with previous studies done to show 
FDG uptake in small AAA subjects66,171-173. 
It has been suggested that a finding of increased FDG uptake is suggestive of 
plaque destabilization and creates concern about adverse events174-175. 
However, I did not have sufficient data to observe any correlation between 




CHAPTER 6  
A novel ultrasound scanning device (AortaScan)176 for 
screening of AAA in the community 
 
6.1 Background 
Screening men for abdominal aortic aneurysm (AAA) with a single ultrasound 
scan prevents deaths from rupture177-179. A National Screening Programme of 
men aged 65years been introduced across England and aims to have full 
coverage by 2013180. Men are invited to visit a screening location, usually in the 
community, for an abdominal ultrasound scan, carried out by a trained 
screening technician using a portable scanner.  
The NAAASP (NHS Abdominal Aortic Aneurysm Screening Programme) will 
require nearly 500 whole-time equivalent screening technicians to undertake all 
the scanning in England181. These technicians are not expected to have prior 
understanding of aortic anatomy or experience of ultrasound scanning. A 
training protocol has been established for these technicians consisting of formal 
didactic training, a minimum number of supervised scans and a competency 
assessment182. It may take up to 6months training before each technician is 
qualified to scan independently within the programme181.  
The success of the screening programme will critically depend on not only 
training the technicians to accurately measure aortic size but also retaining staff 
once trained. Early experience with this model of screening suggests that staff 
training and retention may be the greatest challenge faced by the programme.  
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The use of a portable scanning device that automatically detects AAA with a 
high degree of accuracy would eliminate these training problems. The 
AortaScan BVI 9700 (Verathon Medical UK Ltd) is a portable 3D ultrasound 
instrument (Fig-8) that may have this ability. 
  
6.2 Aims 
To evaluate the accuracy of a novel portable ultrasound scanning device, the 
AortaScan BVI 9700, in the detection of AAA. 
 
6.3 Methods 
Subjects from our local AAA screening and surveillance programs were 
recruited from January 2010 to April 2011. These subjects were either known to 
have AAA (based on previous ultrasound, CT or MR imaging) or a normal aorta 
(based on screening using conventional ultrasound). AAA was defined as 
diameter >3cm. Subjects with body mass index (BMI) >35 kg/m2 were excluded 
from the study to limit CT radiation dose. This study is a part of National 
Institute for Health Research (NIHR) programme into aortic disease approved 
by the local research ethics committee (07/Q0702/62). A short medical history 
was taken and BMI was measured on recruitment.  
6.3.1 AortaScan 
      All subjects underwent assessment with the AortaScan AMI 9700 (Verathon 
Medical UK, Fig 6-1).  
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Fig 6-1: AortaScan AMI 9700183 
This device automatically assesses the aortic diameter with minimal user skills. 
It uses a 13mm diameter 3.0 MHz transducer with a penetration depth of 18cm. 
The aorta is detected using differences in echo-density between the vessel and 
surrounding tissues, and the device derives the diameter from the measured 
sac volume. All scans were performed by the same operator (MC) blinded to the 
presence of AAA. Prior to the study the operator was trained to use the device 
according to the manufacturer advice. This training consisted of reading a four-
page instruction booklet, watching the onboard video tutorial (4mins) and a 
10min familiarisation session with a representative from the device 
manufacturer. 
Subjects were scanned supine in a temperature-controlled relaxed environment. 
The abdomen was exposed and the scan performed according to the 
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Instructions For Use183. The probe is sequentially placed at four midline 
positions from the xiphisternum to the umbilicus. Scanning is activated by 
pressing a button on the probe and takes less than 3secs at each position. The 
aortic maximum diameter is calculated and a colour LCD screen display 
indicates either a normal aorta or the aortic diameter if greater than 3cm (Fig 6-
2). The greatest diameter, measured at each of the 4 positions, was taken as 
the value to compare to the true maximum diameter (determined by CT). The 
data were uploaded to a dedicated image management software package 










Fig 6-3: B-mode image on ScanPoint: aneurysm measuring 4.5cm(v mode) and 
4.2cm(manual) 
6.3.2 CT-Scan 
All patients underwent aortic CT within 8wks of the AortaScan. Non-contrast 
enhanced images were obtained on a 16-slice helical scanner with a 3mm slice 
thickness (Brilliance CT, Philips, Eindhoven, Netherlands). Osirix (v3.9) imaging 
software was used to measure the aorta. AAA was defined as an aorta with an 
anterior-posterior (inner to inner) diameter of ≥3cm. 
6.3.3 Statistics 
Differences between the control and AAA groups were analysed using unpaired 
t-test for continuous data. A P-value less than 0.05 (two sided) was considered 
significant. Sensitivity and specificity was calculated using contingency table. 
The data was analysed using SPSS version 19.0 statistical software (SPSS 




6.4 Results  
A total of 91 subjects underwent imaging with AortaScan and CT (mean age 
68.5 years). 43 subjects had AAA confirmed by CT and 48 subjects had a 
normal sized aorta (<3 cm diameter). The mean CT-aortic diameter was 3.7 cm 
(range 3-5.5 cm) in AAA subjects and 2 cm (1.5-2.9 cm) in control subjects. 
Subject demographics are shown in (Table 6-1). 
Table 6-1: Subject demographics  
 
The AortaScan correctly detected AAA in 35/43 subjects (sensitivity 81%) with 
false positives in 13 subjects who did not have AAA (specificity 72%). The 










 AAA (n=43) Control (n=48) P-value 
Age (years) 71 (64-81) 66 (65-68)  0.0001 
CT-Aortic diameter (cm) 3.7 (3-5.5 cm) 2 (1.5-2.9 cm)  
Body mass index (kg/m2)  26.43 (16-35) 26.10 (19-33) 0.647 
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Table 6-2: Contingency table showing accuracy of AortaScan vs CT-scan 
 
 
The aneurysms missed by the AortaScan ranged from to 3.6 cm to 4.4cm in 
size (mean 3.85 cm). There was no difference in mean BMI between the two 
groups. Comparisons of AortaScan results from patients with normal BMI (18.5-
25 kg/m2) and abnormal BMI (<18.5 or >25 kg/m2) showed no effect of BMI on 






 BVI 9700 
                        CT Scan 
AAA (yes) AAA (no)  
AAA (yes) 35  13  Positive predictive value 
72%  
AAA (no) 8  35  Negative predictive 
value 81% 
 Sensitivity 81% Specificity 72%  
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Fig 6-4: BMI had no significant effect on AortaScan results (P=0.157 Chi2analysis)   
 
6.5 Discussion 
Consensus exists across guidelines on one-time screening of elderly men to 
detect and treat AAAs 5.5cm184. Screening for any disease requires a test that 
is accurate, easily available and cost-effective (i.e. the use of relative 
inexperienced scanning technicians rather than trained sonographers). The 
AortaScan AMI 9700 is a novel automated ultrasound device designed to detect 
the presence of an AAA, with minimal training of the operator185.  In this study 
we have compared the result of assessment of aortic size by AortaScan with 
that of the ‘gold’ standard measure of anatomical size, CT, in order to examine 
the accuracy of this device and to determine whether the AortaScan could have 
a role within an AAA screening programme.  
 
 95 
The manufacturers of the device do not claim that the AortaScan will provide an 
accurate size of the aorta, only that the device indicates that the aorta is either 
normal (i.e. <3cm diameter) or >3cm diameter (with an estimate of size if the 
latter). The AortaScan should therefore only be considered for screening rather 
than surveillance.  Patients with detected small aneurysms would need to enter 
a surveillance programme that employs conventional ultrasound 
measurements. Future developments of the device may overcome this 
limitation.  
The results of our study show the sensitivity of the AortaScan is 81% when 
compared with CT.  The sensitivity of the device in its current form is therefore 
not sufficient for its introduction into an AAA screening programme. Factors that 
affect accuracy may include patient morphology, vessel tortuosity and the 
presence of thrombus within the sac. Although we found no significant 
relationship between incorrect results and BMI there was a trend towards a 
greater BMI in those subjects with false negative results. No patients in this 
study had severe tortuosity, and as the CT scans were performed without 
contrast, we were unable to analyse whether thrombus had any effect on 
accuracy. We understand the manufacturers are currently working to increase 
the accuracy for the next generation of the device. 
In this study we have confined testing to patients with small (i.e. <5.5 cm 
diameter) AAA. These would make up the majority of AAA detected in the 
screening programme37. It could be anticipated that for larger AAA the device 
would be more sensitive.  
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Assessment of the accuracy of the previous AortaScan model against 
conventional ultrasound rather than CT showed a 90% sensitivity and 94% 
specificity to detect AAA45. The conventional ultrasound also suffered from a 
number of false positives and false negatives, rendering the results difficult to 
interpret. Little information was reported regarding factors that affected false 
results. One possible explanation for a greater sensitivity in that study is that the 
mean aortic diameter was larger than in ours (3.9 cm vs 2.8 cm). 
Evidence is emerging that patients with dilated aortas that do not currently meet 
the definition of AAA (i.e. measuring 2-3 cm in diameter) may also dilate over 
time and eventually be at risk of rupture186. These patients may in future be 
included on surveillance programmes and so devices such as AortaScan will 
also need to be able to accurately detect these small diameter aortas. 
Trials demonstrating the efficacy of AAA screening have used trained 
sonographers to screen a limited population13 37. The number of scans, 
however, required in a national programme far exceed the capacity available for 
sonographers to perform, and so the model adopted by the NAAASP relies on 
training personnel previously unskilled in ultrasound to perform the screening 
scans. Although conventional ultrasound can achieve a very high sensitivity and 
specificity this requires a prolonged training programme to achieve a minimum 
level of operator ability. There are concerns that in practice it may be difficult to 
achieve a consistent level of quality from inexperienced scanning personnel. An 
additional challenge is to maintain staff retention after training. An automated 
ultrasound scanner to detect AAA would eliminate these problems. 
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The availability of an automatic device to accurately detect AAA with minimum 
operator training would greatly increase the chance of delivering a 
comprehensive and effective screening programme. 




CHAPTER 7  
General discussion and future studies 
 
Abdominal aortic aneurysmal disease (AAA) is a significant contributor to 
morbidity and mortality, in particular in men over the age of 65 years.  
Understanding the processes that lead or contribute to aortic dilatation, in 
conjunction with effective screening for this condition, should significantly 
improve our management of this disease. The aims of my thesis were therefore 
to investigate the relationship between aortic stiffness, calcification and AAA, 
and to assess a novel ultrasound-based device for use in AAA screening 
programmes. 
7.1 Evaluation of tonometry and CMR to measure aortic 
stiffness  
cfPWV is gold standard way to measure aortic stiffness121-123,187 but it does not 
give any information on regional aortic stiffness.  The concept of regional aortic 
stiffness became popular because these changes in aortic stiffness may 
precede aortic remodeling or aneurysm formation.  In the present study, 
tonometry and CMR had a modest agreement in the measurement of aortic 
PWV. PWV-CMR produced PWVs that were lower than those measured by 
cfPWV, which is in keeping with the results of others130. This is most likely as a 
result of the different path measured by each method. cfPWV includes carotid 
and iliac arterial beds, whereas CMR only measures PWV from aortic root to 
bifurcation of aorta.  
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MRI has been used to measure PWV along the aortic segments to show 
changes in regional aortic stiffness83. PWV tends to increase in the distal 
segments of aorta130 suggesting the distal aorta is stiffer, data that has been 
confirmed by invasive catheter measurements131. Post-operative measurement 
of PWV by Doppler echocardiography of the descending thoracic aorta of 
patients with infra-renal AAA, has suggested that a low PWV or high 
compliance in the thoracic aorta leads to AAA rupture86 .They also suggest that 
a PWV > 15m/sec is associated with a very rigid aorta, therefore in such 
subjects AAA may rupture due to increased wall stress, this observation is 
based on data from two subjects. Finally, they concluded that a higher thoracic 
compliance might be related to faster growth of the AAA and earlier rupture. 
However, the main limitation of their study is that PWV is measured in thoracic 
aorta following AAA repair and sample size is small. 
7.2 Aortic stiffness and AAA 
Aortic stiffness or pulse wave velocity is an independent predictor of 
cardiovascular events and is known to increase with age. The aorta is subject to 
repetitive cyclic stress, which may lead to fragmentation and breakdown of the 
elastic components of the aortic media, particularly elastin and collagen. One 
hypothesis is that these histological changes lead to stiffening and dilation of 
the aortic wall21. Indeed, there is a well-established relationship between age-
related increase in aortic stiffness and diameter130. Preliminary observations 
also suggest an association between aortic stiffness and aortic diameter dilation 
in patients with abdominal aortic aneurysm80.  
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We used two methods to measure aortic stiffness - applanation tonometry121 
and MRI129. Tonometry measures stiffness in the entire aorta, but MRI can also 
measure segmental aortic stiffness. The results from both techniques revealed 
that subjects with AAA have stiffer aorta than normal men of a similar age; 
which was not unexpected, as our AAA patients are known to be vasculopaths, 
a finding that is supported by the significantly greater CIMT in these subjects in 
this study. 
Carotid-femoral PWV analysis showed a generally stiffer whole aorta in patients 
with AAA. Measurement of aortic PWV by CMR revealed that stiffness does not 
vary along its length in patients with AAA, while in control subjects; the 
abdominal segment was stiffer than that of the thoracic segments. Thoracic 
segment was significantly stiffer in AAA patients than in control subjects, 
although the stiffness of the abdominal segment was similar in both groups. 
Aging is associated with increased stiffness in both the thoracic and abdominal 
aorta in the general population83,130.  The finding of similar abdominal PWV in 
patients with AAA and controls is, at first sight, surprising since aneurysmal 
disease is characterised by medial degeneration expected to increase intrinsic 
stiffeness of the wall20. One explanation is that an increase in intrinsic stiffening 
of the wall of the abdominal aorta may be offset by the inverse relation of PWV 
to aortic diameter. According to the Moens-Korteweg equation, PWV = √Eh/D 
where E = elastic modulus, a measure of intrinsic stiffness, h = wall thickness 
and D = diameter. Thus, for a given elastic modulus and wall thickness, a larger 
aortic diameter would result in a lower PWV. Differences in abdominal aortic 
diameter between AAA patients and control subjects may thus mask differences 
in intrinsic aortic elasticity. A recent study has also shown an association 
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between arterial stiffness measured by tonometry and ascending aortic 
dilatation188. 
The studies reporting segmental aortic stiffness in literature are done on 
subjects with normal aortic diameter and our control group data is in keeping 
with these studies. The studies, which report relationship of aortic stiffness or 
PWV with AAA, have not either measured segmental aortic stiffness or stiffness 
is measured after the AAA has been repaired86,133,189.  
Stiffness increases with age and our AAA group was older than control group. 
Similarly AAA subjects were vasculopaths, with the CIMT significantly thicker in 
AAA subjects and all known risk factors for cardiovascular disease were 
common in this group. Our demographic data showed that systolic hypertension 
is more prevalent in the AAA group. We therefore used multivariate analysis to 
adjust for these factors and found that cfPWV was independently, positively 
correlated with AAA disease. Logistic regression showed that the risk of 
developing AAA increases over 3.1-fold for every 1m/s increase in cfPWV. MAP 
showed a significant association with AAA.  
 
Studies have shown that hypertension is prevalent in AAA subjects. Pressure-
strain elastic modulus (Ep) as described earlier (Chapter-1) is also a measure of 
arterial stiffness like PWV. In one study Ep was measured in AAA subjects and 
age matched controls using ultrasound. They found AAA subjects had stiffer or 
less elastic aortas than controls and there was no relationship between aortic 
diameter and aortic stiffness20. It is difficult, however, to measure Ep in the AAA 
wall as there is often thrombus present and imaging cannot distinguish between 
this and the true wall. The presence of thrombus may therefore give rise to 
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erroneous Ep readings. Histological specimens have confirmed that aneurysmal 
aortas are less elastic than age matched aortas190.  
Assessment of a relationship between aortic stiffness and aneurysm growth rate 
was analysed with the aid of a linear model as we had a linear trend in growth 
of AAA in our cohort of patients. Our data suggests that the bigger an aneurysm 
is at presentation the faster it grows, which is in keeping with a recently 
published meta-analysis191. We also observed a trend that an increase in 
cfPWV was associated with a decrease in AAA growth rate, but it was not 
statistically significant. There was no association between segmental PWV and 
AAA growth. Our analysis of the relationship between AAA growth and wall 
stiffness was a retrospective one in which cfPWV was only measured at only 1 
time point. A more precise analysis of the relationship between stiffness and 
growth rate could only be done by measuring both parameters simultaneously.  
We did not find any association between aortic stiffness and CIMT. The mean 
CIMT in our AAA patients and control group is in keeping with other studies in 
AAA subjects111 and healthy population over 60 years old112-113. A higher CIMT 
quartile (Q4) is associated with increased thoracic aortic calcification115-116,118. 
Division of our data set into quartiles, as occurs in most studies112,115 did not 
show any relationship between stiffness (cfPWV) or aortic diameter with 
increasing CIMT quartiles. Our study is however limited by the small number of 
subjects, while most CIMT studies report on data obtained thousands of 
patients119. 
7.3 Aortic calcification 
Calcification of the aorta, like aneurysm formation, is associated with ageing. 
There is evidence that a calcified aneurysm has got a 3-fold increased risk of 
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rupture than a non-calcified aneurysm145.  We found that calcification in the 
entire aorta was significantly higher in AAA patients than control subjects. The 
abdominal aorta was more calcified than the thoracic aorta in both groups. This 
is in keeping with a large study measuring calcification in subjects >60 years in 
multiple vascular beds192. 
Our results showed a fair correlation between aortic stiffness and aortic 
calcification in the entire aorta, as measured by CMR-PWV and CT-scan 
respectively. Surprisingly this correlation disappeared in the abdominal aorta, 
but remained in thoracic aorta on segmental comparison of PWV and calcium 
score. A significant positive association between aortic stiffness and aortic wall 
calcification in healthy subjects of a similar age to those in this study (average 
age 65years) has previously been reported163.  In that study the strength of this 
relationship was poor in ascending aorta and moderate in both the descending 
thoracic and abdominal aorta. Two other groups have found that abdominal 
aortic calcification and aortic stiffness are positively correlated in patients with 
chronic kidney disease164-165. There was no evidence of kidney dysfunction in 
our aneurysm cohort (eGFR). Comparison of our results with other studies is 
difficult as the methods chosen in some studies are subjective and segmental 
division of the aorta also varies.  
The abdominal aorta was the most calcified part of the aorta in both AAA and 
healthy controls. We did not find any correlation between calcification and 
stiffness in the abdominal segment. Our linear regression analysis did, however, 
show that cfPWV and total aortic PWV (PWV-CMR) was significantly, 
independently, positively associated with calcification in abdominal aorta, which 
is in agreement with the work of others163. This observation supports the notion 
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that aortic calcification may contribute to aortic stiffness, but is not the only 
factor causing stiffness21.  
We found a significant inverse relationship between fetuin-A level and aortic 
calcification measured on CT from the aortic root to the bifurcation. A similar 
inverse relationship between plasma fetuin-A and aortic calcification has been 
reported, but the calcified area of the abdominal aorta was measured only at the 
level of L3 and L4 from x-ray computed tomography160.  We did not find a 
correlation between cfPWV and fetuin-A levels.  These results should be 
interpreted with caution, as the size of population studied was small (n=26). A 
larger study (n=185) reported that increased levels of phosphorylated fetuin-A 
containing calciprotein particles (CPP) were independently associated with 
increased aortic PWV169. Our results also suggest that stiffening of abdominal 
aorta is multi-factorial process that involves atherosclerosis, calcification, elastin 
breakdown, medial thinning and accumulation of glycoproteins20.  
 
7.4 AortaScan 
This device had a potential to replace current AAA screening equipment and 
make screening available to patients on a routine visit to their general 
practitioner. We found that AortaScan is a portable and easy to use ultrasound 
device requiring minimal training, but in its current form does not have adequate 
sensitivity in assessing aneurysms. Further technical development is needed in 
order for this device to be considered for use as a screening device for AAA in 
place of conventional ultrasound. 
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7.5 Study limitations 
Our study has a cross-sectional design and includes only subjects with small 
aneurysms with a limited sample size, further longitudinal studies are required 
to see how aortic stiffness changes with age and with increase in diameter of 
aneurysm. The cross-sectional nature of our study precludes conclusions 
regarding causality.  Some MRI scans from PWV analysis were excluded as we 
were getting bizarre flow graphs especially in AAA subjects. There is minimal 
data available how pulse wave progresses in presence of aneurysm.  
Stiffness increases with age and our AAA group was older than control group. 
Similarly AAA subjects were vasculopaths and all known risk factors for 
cardiovascular disease were common in this group, we cannot exclude the 
possibility that they may have influenced the findings. Though, we used 
multivariate analysis to adjust for these factors. 
7.6 Further studies 
A cross-sectional case-control study should be carried out to examine the utility 
of CT and PWV (tonometry) in assessing progression of calcification/ 
stiffness/aortic dilation in relation to systolic hypertension and aneurysm 
formation in a cohort of patients with AAA. This study would show whether there 
is a relationship between the progression of aortic stiffness/calcification and 
aneurysmal disease. The study will allow characterisation of disease patterns 
and refinement of the imaging techniques, which could then be used in more 
extensive investigations that include patients with small AAA detected by the 
National Screening Program. These techniques will lead to a better 
understanding of aneurysm pathophysiology and greater power to predict 
aneurysm expansion and rupture. 
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This study includes only subjects with small AAA; it will be useful to know the 
aortic stiffness in subjects with large AAA. Aortic stiffness was measured only 
once during this study and it will be useful to see variation in PWV in a 
longitudinal study.  
The current guidelines from European Society of Vascular Surgery193 advise 
prescription of antiplatelet agent and statins to all subjects with small AAA 
because they are generally vasculopaths. It has been shown in some studies 
that ‘statins’ reduce aortic stiffness by reduction in plaque volume194-195 and 
similar research in AAA subjects may be useful. There is, however, conflicting 
data on the effects of statin pharmacotherapy on AAA expansion196-197. 
7.7 Summary 
This is the first study to measure segmental biomechanical properties of the 
aorta in patients with small AAA. We found that patients with AAA had 
increased overall pulse wave velocity, measured by cfPWV and CMR. AAA 
subjects had a stiffer thoracic aorta than control subjects. In subjects with a 
normal sized aorta the abdominal segment was considerably stiffer than their 
thoracic aortic segment. We speculate that the tendency for aneurysm 
formation in the abdominal aorta may be a physiological response to the 
increased stiffness that occurs in the thoracic aorta. However, it is equally 
possible that degenerative dilatation may be an independent parallel process to 
stiffness as a consequence of mechanical changes in aging aorta. A 
longitudinal study is required to clarify this cause and effect relationship.  
The techniques outlined in this thesis allow not only delineation of aneurysm 
morphology but also assessment of physiological and metabolic activity. These 
imaging modalities offer the possibility of more accurate risk assessment than 
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simply diagnosis and periodic size measurement, and their use could be 
included, along with measurement of aneurysm size, during surveillance. More 
evidence is, however, needed to know whether this will offer any survival benefit 
and whether they would be cost-effective.  
Further work is required to understand the multiple factors associated with 
aneurysm formation, rupture and growth because some patients with small 




CHAPTER 8  
Appendix 




                                           Patient Radiation Dose Assessment 
 




The study involves one CT of neck, chest, abdomen and pelvis without contrast 
to look at the aorta. The scan extends from the carotid bifurcation to the femoral 
artery. In this submission allowance for additional dose to the patient has been 




CT scan parameters have been estimated as follows: 120kVp, 300mA, 0.75 
second rotation, 225mAs per rotation on 40 x 0.625mm slice acquisition over 
approximately 80cm with an equivalent pitch of 1.2. Estimated Dose Length 
Product (DLP) per scan = 2094mGy.cm. The estimated approximate effective 




Estimated Effective Dose 
 
Patients will undergo one CT examination as part of the study. Doses are 
shown in the table below. The stated doses are for a patient with BMI of 35. It is 
expected that for patients with a BMI less than 35 the dose may be reduced. 
 

















2094 18 1 18 2094 
The European reference levels for diagnostic CT in terms of DLP are as follows; 




The Dose Length Product (DLP) dose constraint set for each CT examination at 
2094mGy.cm is comparable to the sum of the European reference dose levels 
for chest, abdomen and pelvis examinations. This dose constraint applies to 
patients of BMI up to 35. 
 
The total effective dose received by the study subjects of 18 mSv corresponds 
to a total detriment (cancer incidence weighted for lethality and life impairment 
and the probability over two succeeding generations of severe hereditary 
disease) of 1.0 x 10-3 or approximately 1 in 1,000 (ICRP103). The risk factor 
used here relates to the detriment for the whole population that contains a 
range of ages. 
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The level of radiation dose given in this study (18mSv) corresponds to 
approximately 8 years equivalent natural background radiation, where 
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Instructions to prepare platelet poor plasma collection prior to fetuin-A 
measurements: 
1.Collect blood in citrate tubes. 
2.Spin on same day. 
3.Store on ice until spun. (g force: 1500 ; Temp: 4oC; Time: 15 minutes 
3,200 rpm) 
4.Store at -80oC. 
5.Transfer on ice. 
Ultra-centrifuged for 40 mins at 100000g. 
Ca measurements and fetuin sedimentation which might be indicative of mineral 
complexes. 
The best way is to make platelet poor plasma – so the blood samples need to 
be taken with citrate.  The plasma is then centrifuged once at about 2500 rpm 
and then must be ultracentrifuged for 40 mins at 100000g.  If this is not possible 
then the samples will be contaminated with platelets.  This may not be too much 
of a problem as the microparticles can still be isolated by the centrifugations at 
above but it may be harder to make measurements for factors that are not 
related to platelets.  We could however do Ca measurments and fetuin 





































































Figure 8-1: Technology:  V-mode measures ultrasonic reflections in multiple 
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